



*Attachment  
to # 121*

PATENT  
Docket No. 304142000201

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

JUN 05 2001

In the application of:

Malaya CHATTERJEE et al.

Serial No.: 09/293,533

Filing Date: April 15, 1999

For: MONOCLONAL ANTIBODY 1A7 AND  
USE FOR THE TREATMENT OF  
MELANOMA AND SMALL CELL  
CARCINOMA

Examiner: L. Helms

Group Art Unit: 1642

TECH CENTER 1600/2900

DECLARATION OF KENNETH A. FOON, M.D.  
PURSUANT TO 37 CFR § 1.132

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

I, Kenneth A. Foon, declare as follows:

1. I am an inventor on the above-referenced patent application.
2. I am a Professor in the Department of Internal Medicine, Associate Chief of the Division of Hematology and Oncology, and Director of the Barrett Cancer Center at the University of Cincinnati College of Medicine. A curriculum vitae is attached hereto as Exhibit A.
3. I am the director and medical supervisor of clinical trials using anti-idiotypic antibody 1A7 to treat patients with melanoma in accordance with the teachings of the above-

referenced patent application. The details of these trials and data obtained therefrom are summarized in the following paragraphs.

4. In a trial, the details of which are described in Foon et al. (*J. Clin. Oncolgy* (2000), 18:376-384), 47 patients with advanced melanoma (American Joint Committee on Cancer stage IV melanoma with measurable metastatic disease) were administered various doses of TriGem® (TriGem is the registered trademark for monoclonal antibody 1A7) mixed with QS-21 adjuvant, weekly for 4 weeks and then monthly until disease progression. Forty three percent of patients had undergone prior therapy for metastatic disease, 55% had disease confined to soft tissue, and 45% had visceral metastasis.

5. In the trial described in paragraph 4, hyperimmune sera from 40 of 47 patients showed an anti-anti-idiotypic (Ab3) response. The Kaplan-Meier-derived overall median survival duration for the 47 patients was not reached but was at least 16 months, which is superior to those reported from other phase II trials in which the expected survival durations are typically in the range of 5 to 10 months. Most notably, one patient had a complete response, and 12 patients were stable from 14 to 37+ months as of the time of publication of the above-referenced article. The patient who achieved a complete response had multiple soft tissue sites of metastases and had remained in complete remission for 24 months as of the time of publication of the above-referenced article. These results are especially significant given the advanced disease state of the patients. The data from the trial suggest a clinical benefit in using 1A7 to treat patients with advanced melanoma.

6. In a second trial, which is described in Safa et al. (abstract published in Proceedings of American Society of Clinical Oncology (ASCO) (2001), Vol. 20, abstract 1008, attached hereto as Exhibit B; and manuscript submitted for publication, attached hereto as Exhibit C), patients in the adjuvant setting who had curative resection of the primary lesion and lymph node metastases (American Joint Committee on Cancer stage III melanoma) were studied. Patients who had a positive sentinel lymph node biopsy for melanoma had a complete lymphadenectomy. Sixty nine patients were administered antibody 1A7 (25 patients also

received high dose interferon Alfa-2b (HDI). Patients were administered 1A7 for 4 weeks, and then monthly until disease recurrence.

7. In the trial described in paragraph 6, all patients generated active immune responses with high titer anti-GD2 IgG responses and many had measurable CD4 T cell responses. The overall survival (OS) and relapse-free survival (RFS) at a median follow-up of 2 years for patients treated with 1A7 alone (without HDI) was 72% (7 deaths in 44 patients) and 50%, respectively. These data are comparable to those obtained when patients are treated with HDI, which are 78% (OS) and 62% (RFS), as reported in a personal communication from Dr. John Kirkwood of the Division of Hematology-Oncology and Department of Pathology, Department of Medicine, University of Pittsburgh Cancer Institute Melanoma Center, University of Pittsburgh Medical Center, Pittsburgh, PA. Dr. Kirkwood obtained this data from a two-year analysis of a trial comparing HDI with a GMK ganglioside vaccine in patients with high risk resected stage IIb and III melanoma. HDI has previously been reported to be beneficial for treating melanoma patients (see, for example, Kirkwood et al., *J. Clin. Oncol.* (1996), 14:7-17; Kirkwood et al., *J. Clin. Oncol.* (2000), 18:2444-2458; and Kirkwood et al., *Annals of Oncology* (2000), Supp. 4 to Vol. 11). Thus, the data from the trial described in paragraph 6 suggest a clinical benefit in using 1A7 for treatment of melanoma.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

Date

5/29/01

Kenneth A. Foon, M.D.

Kenneth A. Foon

**KENNETH A. FOON, M.D.  
PROFESSOR, DEPARTMENT OF INTERNAL MEDICINE  
ASSOCIATE CHIEF, DIVISION OF HEMATOLOGY AND ONCOLOGY  
AND DIRECTOR, THE BARRETT CANCER CENTER  
UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE**

**I. PERSONAL DATA**

Home Address: 1113 Belvedere St.  
Cincinnati, OH 45202

Home Telephone: (513) 651-3598

Office Address: The Barrett Cancer Center  
University of Cincinnati  
234 Goodman St., Suite 1091  
Cincinnati, OH 45267-0502

Office Telephone: (513) 584-7698  
Office Fax: (513) 584-5680  
E-Mail Address: kenneth.foon@uc.edu

Social Security #: 372-48-6164

NCI Investigator #: 10881

Birth Date: March 7, 1947

Certification: 1973, Diplomate, National Board of Medical Examiners  
1978, Diplomate, American Board of Internal Medicine  
1980, Diplomate, Subspecialty of Hematology, American Board of  
Internal Medicine  
1981, Diplomate, Subspecialty of Medical Oncology, American Board  
of Internal Medicine

OH License No. 76212

Marital Status: Married

Spouse Name: Rebecca A. Garrett, M.D.

Children: Melissa G. Foon (2/5/79)  
Michele G. Foon (10/2/80)  
Jeremy G. Foon (6/12/85)

II. EDUCATION

1964 - 1966 University of Michigan  
1966 - 1968 B.S., Wayne State University  
1968 - 1972 M.D., Wayne State University

III. PROFESSIONAL EXPERIENCE

1977 - 1980 Hematology-Oncology Fellowship, University of California, Los Angeles, School of Medicine, Los Angeles, CA  
1976 - 1977 Junior Assistant Resident, Washington VA and Georgetown University Hospitals, District of Columbia  
1975 - 1976 Clinical Associate, Laboratory of Microbiology and Immunology, National Institute of Dental Research, National Institutes of Health, Bethesda, MD  
1973 - 1975 Research Associate, National Eye Institute; Guest Worker, Laboratory of Microbiology and Immunology, National Institute of Dental Research, National Institutes of Health, Bethesda, MD  
1972 - 1973 Straight Medicine Internship, University of California, School of Medicine, San Diego, CA

IV. ACADEMIC APPOINTMENTS

1999 - present Professor, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH  
1993 - 1999 Professor, Department of Internal Medicine, University of Kentucky, Lexington, KY  
1991-1992 Adjunct Member, Department of Molecular and Experimental Medicine, The Scripps Research Institute  
1987-1991 Professor, Department of Medicine, State University of New York at Buffalo, NY  
1985-1987 Associate Professor, Department of Medicine, University of Michigan, Ann Arbor, MI

1984-1985 Associate Professional Lecturer in Medicine, George Washington  
1981-1985 Senior Investigator, National Cancer Institute, Frederick, MD

1980-1981 Assistant Professor, Department of Medicine, University of California,  
Los Angeles, School of Medicine, Los Angeles, CA

V. HOSPITAL OR CLINICAL APPOINTMENTS

1999 – present Director, The Barrett Cancer Center and Associate Director, Division  
of Hematology-Oncology, Department of Internal Medicine,  
University of Cincinnati, Cincinnati, OH

1993 – 1999 Director, Lucille Parker Markey Cancer Center and Chief, Division  
of  
Hematology and Oncology, Department of Internal Medicine,  
University of Kentucky, Lexington, KY

1991 – 1992 Associate Director for Clinical Research, Ida M. and Cecil H. Green  
Cancer Center, Scripps Clinic and Research Foundation; Adjunct  
Member, Department of Molecular and Experimental Medicine, The  
Scripps Research Institute, La Jolla, CA

1987 – 1991 Chief, Division of Clinical Immunology, Roswell Park Cancer  
Institute, and Professor, Department of Medicine, State University of  
New York at Buffalo, NY

1985 – 1987 Associate Chief and Director of Clinical Hematology, Division of  
Hematology and Oncology, and Associate Professor, Department of  
Medicine, University of Michigan, Ann Arbor, MI

1982 – 1985 Head, Clinical Investigations Section, Biological Therapeutics  
Branch, Biological Response Modifiers Program, Division of Cancer  
Treatment, National Cancer Institute-Frederick Cancer Research  
Facility, Frederick, MD

1984 – 1985 Associate Professorial Lecturer in Medicine, George Washington  
University, School of Medicine and Health Sciences, District of  
Columbia

1981 – 1982 Head, Monoclonal Antibody-Hybridoma Section, Biological  
Therapeutics Branch, Biological Response Modifiers Program,  
Division of Cancer Treatment, National Cancer Institute, Frederick,  
MD

1980 – 1981      Assistant Professor of Medicine, University of California, Los Angeles School of Medicine, Los Angeles, CA.

VI. CONSULTING

1985 – 1988      Board of Advisors, NeoRx Corporation, Seattle, WA

May 1, 1985      P01, Member, Memorial Sloan Kettering Cancer Center, NCI Site Visit Committee, New York, NY

October 1, 1985      P01, Member, NCI Special Review Committee

October 1, 1985      P01, Member, Stanford Medical Center, NCI Site Visit Committee, Stanford, CA

1985 – 1989      National Research Service Award Advisory Committee, National Institute of Health

March 1, 1988      P01, University of California at Davis, Sacramento, CA, Member, NCI Site Visit Committee

December 5, 1990      P01, Member, Immunomedics, Site Visit Committee, Morris Plains, NJ

November 11, 1991      P01, Stanford Medical Center, Member, NCI Site Visit Committee, Stanford, CA

February 10, 1992      P30, Member, University of Nebraska Cancer Center, NCI Site Visit Committee, Omaha, NE

July 13, 1993      P50, Member, NCI Special Study Section for AIDS Center Grants

1994 – 1995      Board of Advisors, Inex Pharmaceuticals Corp., Vancouver, B.C.

1994 - 1996      Health and Environment Laboratories, Eastman Kodak Company, Rochester, NY

April 13, 1994      P01, University of California at Davis, Sacramento, CA, NCI Site Visit Committee Chairman

June 19, 1994      2P01CA59326-03, Gene Therapy for Cancer, University of California at Los Angeles, Member, NCI Site Visit Committee

1995 -present      Scientific Review Panel, Israel Cancer Research Fund, New York, NY

February 14, 1995	2P01CA4499108, Therapy of Lymphoma/Leukemia with Monoclonal Antibodies, Fred Hutchinson Cancer Research Center, Member, NCI Site Visit Committee
June 12, 1995	1P30CA6953301, Oregon Cancer Center, Member, NCI Site Visit Committee
August 3, 1995	1P30CA6953301, Oregon Cancer Center, Member, NCI Site Visit Committee
February 6, 1996	NSABP Scientific Advisory Board, Operations Center Site Visit, Pittsburgh, PA
July 7, 1996	2P01CA5935005, Memorial-Sloan Kettering Cancer Center, Gene Therapy Program, NCI Site Visit Committee Chairman
October 7, 1996	1P30CA6953301A1, Oregon Cancer Center, Member, NCI Site Visit Committee
1996 - present	Director, Scientific Advisory Board, Titan Pharmaceuticals, Inc., South San Francisco, CA.
1997 - present	NCI Scientific Review Group-Subcommittee H
1999 - present	NCI Clinical Oncology Study Section
September 21, 1999	ACOSOG Site Visit, Chicago, IL
January 15, 2000	SuperGen Advisory Board Meeting, Phoenix, AZ.
January 13-16, 2000	SuperGen Advisory Board Meeting, Phoenix, AZ.
February 15, 2000	NCI GI Intergroup State-of-Science Symposium
March 20, 2000	NCI Clinical Oncology Study Section, Bethesda, MD
May 7-8, 2000	IDEC Pharmaceuticals Meeting, San Diego, CA
May 16, 2000	American College of Surgeons/Titan Pharmaceuticals Meeting, Chicago, IL
June 7-9, 2000	NCI NIH Scientific Review Group - Subcommittee H Site Review, Rochester, MN
June 13-17, 2000	SuperGen, Rubitecan Advisory Board Meeting, Maui, HI



June 24, 2000	American College of Surgeons Semiannual Meeting, Chicago, IL
July 7-14, 2000	NCI Clinical Oncology Study Section, Bethesda, MD
Dec. 8-9, 2000	Abbott Pharmaceutical Advisory Panel, Chicago, IL
Jan. 14-15, 2001	Fulcrum Renal Cell Advisory Board Mtg. New York
Jan. 18-19, 2001	NCI Breast Intergroup Retreat, Washington, DC.
Mar. 15, 2001	NCI Scientific Review Group – Subcommittee H Teleconference

## VII. TEACHING ACTIVITIES

Biotherapy: New Opportunities for Cancer Treatment, Grand Rounds, Scripps Clinic and Research Foundation, La Jolla, CA, February 28, 1992

Acute Leukemia, Internal Medicine Residency Program, University of Kentucky Medical Center, Lexington, KY, August 16, 1993.

Hodgkin's Disease, Hematology/Oncology Fellows Board Review Lecture Series, University of Kentucky Medical Center, September 10, 1993.

Biologic Therapy and Growth Factors, Hematology/Oncology Fellows Board Review Lecture Series, University of Kentucky Medical Center, October 8, 1993.

Anti-Idiotypic Immunotherapy in Cancer Patients, Lecture-Division of Clinical Chemistry, University of Kentucky Hospital, Lexington, KY, April 27, 1994.

Chronic Lymphocytic Leukemia, Internal Medicine Grand Rounds, University of Kentucky Medical Center, Lexington, KY, July 6, 1994.

Acute Leukemia, Internal Medicine Residency Program, University of Kentucky Medical Center, Lexington, KY, August 16, 1994

Anti-Idiotypic Vaccine Therapy of CEA positive tumors, Internal Medicine Research Seminar, University of Kentucky Medical Center, Lexington, KY, September 8, 1994.

Melanoma, Hematology/Oncology Fellows Board Review Lecture Series, University of Kentucky Medical Center, February 3, 1995.

Lymphoma, Internal Medicine Residency Program, University of Kentucky Medical Center, Lexington, KY, March 23, 1995.

Chronic Lymphocytic Leukemia, Internal Medicine Residency Program, University of Kentucky Medical Center, Lexington, KY, April 28, 1995.

Overview of the Cancer Center, Health Administration, University of Kentucky Medical Center, June 22, 1995.

Non-Hodgkin's Lymphoma, Internal Medicine Residency Program, University of Kentucky Medical Center, Lexington, KY, September 11, 1995.

Hodgkin's Disease, Hematology/Oncology Fellows Board Review Lecture Series, University of Kentucky Medical Center, September 15, 1995.

Non-Hodgkin's Lymphoma, Hematology/Oncology Fellows Board Review Lecture Series, University of Kentucky Medical Center, September 29, 1995.

Acute Leukemias, Hematology/Oncology Fellows Board Review Lecture Series, University of Kentucky Medical Center, February 2, 1996.

Leukemia and Lymphoma, Physician Assistants Lecture, University of Kentucky Medical Center, March 7, 1996.

Problem Based Learning Tutor Session, Internal Medicine, University of Kentucky Medical Center, April 1-15, 1996.

Low Grade Lymphomas, Hematology/Oncology Fellows Board Review Lecture Series, University of Kentucky Medical Center, June 28, 1996.

Acute Leukemia, Internal Medicine Residency Program, University of Kentucky Medical Center, Lexington, KY, August 8, 1996.

Melanoma, Hematology/Oncology Fellows Board Review Lecture Series, University of Kentucky Medical Center, August 16, 1996.

A Novel Immunotherapeutic Approach for the Adjuvant Treatment of Colon Cancer, Internal Medicine Grand Rounds, University of Kentucky Medical Center, Lexington, KY, September 4, 1996.

Lymphomas, Internal Medicine Residents, University of Cincinnati Hospital, September 14, 1999.

Lymphomas, Internal Medicine Residents, University of Cincinnati Hospital, October 4, 1999.

Melanoma, Internal Medicine Residents, University of Cincinnati Hospital, Cincinnati, OH, December 9, 1999.

Lymphomas, Internal Medicine Residents, University of Cincinnati Hospital, January 6, 2000.

Cancer Research, Division of Pharmacology, Ph.D. Program, University of Cincinnati College of Medicine, January, 7, 2000.

Anti-Idiotypic Cancer Vaccines, Children's Hospital Medical Center Research Foundation, Basic Scientists, January 31, 2000.

Melanoma, Internal Medicine Residents, University of Cincinnati Hospital, June 24, 1999.

Lymphomas, Internal Medicine Residency Program, University of Cincinnati, Cincinnati, OH, January 6, 2000.

Cancer Research, Division of Pharmacology, Ph.D. Program, University of Cincinnati, OH, January 7, 2000.

Anti-Idiotypic Cancer Vaccines, Children's Hospital Medical Center Research Foundation, Basic Sciences, Cincinnati, OH, January 31, 2000.

Lymphoma, Internal Medicine Residency Program, University of Cincinnati, Cincinnati, OH, March 13, 2000.

Melanoma, Internal Medicine Residency Program, University of Cincinnati, Cincinnati, OH, April 14, 2000.

Non-Hodgkin's Lymphoma, Internal Medicine Residency Program, University of Cincinnati, Cincinnati, OH, June 26, 2000.

Colon Cancer, Internal Medicine Residency Program, University of Cincinnati, Cincinnati, OH, September 27, 2000

Chronic Lymphoid Leukemias, Hematology-Oncology Grand Rounds Conference, University of Cincinnati, Cincinnati, OH, September 28, 2000.

## VIII ADVISING ACTIVITY

Internal Medicine Resident, University of Cincinnati College of Medicine, September, 1999.

**IX. ADMINISTRATIVE ACTIVITY AND UNIVERSITY SERVICE**

1989 - 1990 Search Committee for Chairman, Department of Radiation Oncology,  
1989 - 1990 Search Committee for Chairman, Department of Cytogenetics, Roswell  
1989 - 1990 Search Committee for Chairman, Department of Pediatrics, Roswell  
1990 Head, Search Committee for Infectious Disease Specialist, Roswell Park  
Cancer Institute  
1990 - 1991 Search Committee for Chairman, Department of Microbiology, SUNY  
1989 - 1990 Radiation Safety Committee, Roswell Park Cancer Institute  
1989 - 1990 Quality Assurance Committee, Roswell Park Cancer Institute  
1989 - 1991 American Society of Hematology, Neoplastic Committee  
1990 Head, Search Committee for Pulmonologist/Intensivist, Roswell Park  
1991 Head, Search Committee for Cardiologist, Roswell Park Cancer Institute  
1990 - 1991 Vice President, Medical Staff, Roswell Park Cancer Institute  
1993 Head, Search Committee for Chairman of Radiation Medicine,  
1989 - 1991 American Society of Clinical Oncology, Program Committee  
1991 - 1992 American Association for Cancer Research, Program Committee  
1992 - 1994 Clinical Immunology Society, Program Committee  
1992 -present Internal Medicine Chairman's Advisory Committee  
1994 -present Liaison Committee on Medical Education, University of Kentucky of  
Kentucky  
1994 - 1996 Medical Center Clinical Sciences Area Advisory Committee, University  
of Kentucky  
1996 - 1999 General Clinical Research Center Advisory Committee, University of  
Kentucky  
1999 -present Chair, Cancer Steering Committee, University Hospital, University of  
Cincinnati  
1999 -present Vontz Steering Committee, University of Cincinnati  
1999 -present Chair, Internal Advisory Committee, Barrett Cancer Center, University of  
Cincinnati  
1999 -present Chair, Scientific Review Committee, Barrett Cancer Center, University of  
Cincinnati  
1999 -present Hematology-Oncology Fellow Evaluation Committee, University of  
Cincinnati  
1999 -present Ohio Cancer Incidence Surveillance System Advisory Board  
Ohio Department of Health  
1999 -present Oncology-Hematology Care Executive Committee, University of  
Cincinnati

**X. SPECIAL ASSIGNMENTS**

Not applicable.

## XI. HONORS

- 1971 Alpha Omega Alpha
- 1972 Medical degree awarded with high distinction, Wayne State University
- 1971 Dr. A. Ashley Rousuck Award in Internal Medicine
- 1972 Gordon B. Myers Award in Internal Medicine
- 1982 Fellow of the American College of Physicians
- 1982 - 1996 Editorial Board, Journal of Immunotherapy
- 1986 - 1990 Clinical Sciences Study Section (Subcommittee 4), Division of Research Grants,
- 1987 Distinguished Alumni Award
- 1987 - 1990 Associate Editor, Antibodies, Immunoconjugates and Radiopharmaceuticals
- 1987-present Associate Editor, Cancer Research
- 1988 Michigan Science Trailblazer
- 1990 - 1994 Editorial Board, Contemporary Oncology
- 1993-present Editorial Board, Journal of Clinical Immunology
- 1993 - 1996 Grants Review Committee for the American Cancer Society
- 1995 - 1997 Board of Directors, The Society for Biological Therapy
- 1995-present Editorial Board, Journal of Biotherapy
- 1996-present Member, Scientific Advisory Board, National Surgical Adjuvant Breast and Bowel Project
- 1998-present Associate Editor, Clinical Cancer Research
- 1998 Faculty Research Award for Excellence in Research, University of Kentucky, Department of Internal Medicine
- 1998 Chairman's Award for Excellence in Research, University of Kentucky Department of Internal Medicine
- 2001 - present Editorial Board, CURE: Cancer Updates, Research and Education, Dallas TX

## XII. PROFESSIONAL ACTIVITY AND PUBLIC SERVICE

### Societies:

- 1978 American College of Physicians, Member (1982, Fellow)
- 1980 American Society of Hematology
- 1980 American Association for the Advancement of Sciences
- 1981 American Society of Clinical Oncology
- 1982 American Association for Cancer Research
- 1982 The Society for Biological Therapy
- 1985 - 1987 Board of Trustees, Michigan Chapter, Leukemia Society of America
- 1987 Clinical Immunology Society
- 1987-present Member, Leukemia Committee, Southwest Oncology Group
- 1991 International Society for Experimental Hematology
- 1994 American Cancer Society, Board of Directors, Fayette County Unit

1997- present Member, Colorectal Disease Committee, National Surgical Adjuvant  
Breast and  
Bowel Project

1997- present Member, Melanoma Committee, Southwest Oncology Group  
1998 Department of Insurance, Commonwealth of Kentucky  
1999-present Member, Colorectal Committee, American College of Surgeons

### XIII. SPEAKING ENGAGEMENTS

1992

#### Local

Advances in Systemic Treatment of Melanoma Cutaneous Malignancies, 1992 Skin Cancer  
Update, Scripps Clinic and Research Foundation, La Jolla, CA, February 1, 1992.

Lymphoid Malignancies: Novel Biotherapeutic Approaches, The 10th Annual Conference of  
Clinical Hematology and Oncology: 1992, Scripps Clinic and Research Foundation, La Jolla, CA,  
February 18, 1992.

Flow Cytometry and Immune Surface Markers in Hematologic Malignancies, The 10th Annual  
Conference of Clinical Hematology and Oncology: 1992, Scripps Clinic and Research Foundation,  
La Jolla, CA, February 18, 1992.

The Cytokine Network 1992: Enhancing Definitive Therapy, Scripps Clinic and Research  
Foundation, La Jolla, CA, May 15, 1992.

Newer Biologic Approaches to Treatment of Lymphoma and Leukemia, 18th Annual Lukes  
Conference, Scripps Clinic and Research Foundation, La Jolla, CA, October 15, 1992.

#### State

Biological Response Modifiers: Innovative Approaches to Cancer Therapy, Memorial Cancer  
Institute, Long Beach, CA, May 27, 1992.

Chronic Lymphocytic Leukemia: Recent Biologic and Therapeutic Advances, Grand Rounds,  
University of Southern California, School of Medicine, Los Angeles, CA, July 31, 1992.

Chronic Lymphocytic Leukemia in the 1990s, Medical Grand Rounds, King Drew Medical Center,  
Los Angeles, CA, August 4, 1992.

Chronic Lymphoid Malignancies, Berlex Corporation, San Francisco, CA, September 22, 1992.

Chronic Lymphocytic Leukemia, Grand Rounds, Western Medical Center, Santa Ana, CA, September 23, 1992.

Biologic Therapy of Cancer, Medical Grand Rounds, Mercy Hospital, San Diego, CA, November 2, 1992.

Chronic Lymphocytic Leukemia, Medical Grand Rounds, Long Beach VA Hospital, Long Beach, CA, November 19, 1992.

Chronic Lymphocytic Leukemia, Oncology Grand Rounds, University of California Irvine, Orange, CA, November 23, 1992.

Anti-Idiotypic Antibodies: New Approaches to Cancer Therapy, City of Hope, Duarte, CA, December 15, 1992.

#### National

Chronic Lymphocytic Leukemia in the 1990s, Bethesda Naval Hospital, Bethesda, MD, June 18, 1992.

Anti-Idiotypic Antibodies: Novel Therapeutic Approaches to Cancer Therapy, University of Kentucky Medical Center, Lexington, KY, August 18, 1992.

Chronic Lymphoid Malignancies, Medical Grand Rounds, Providence Hospital, Detroit, MI, August 26, 1992.

Chronic Lymphocytic Leukemia, Arizona Oncology Society, Phoenix, AZ, December 12, 1992.

#### International

Lymphocytic Leukemias: New Insight Into Biology and Therapy, Leukemia '92, 2nd International Course, Genoa, Italy, July 4, 1992.

1993

#### Local

The Staging and Treatment of Lymphomas, Kentucky Cancer Registry's Annual Workshop for Tumor Registrars, Lexington, KY, September 10, 1993.

#### State

Principles of Biological Response Modifiers, American Cancer Society: Cancer Nursing Course, Louisville, KY, April 21, 1993.

#### National

Current Approaches to Chronic Lymphoid Malignancies and Immune Therapy in Hematologic Malignancies, 11th Annual Conference Clinical Hematology and Oncology, Scripps Clinic and Research Foundation, La Jolla, CA, February 14, 1993.

Biology and Therapy of AML, AML Grant Round Lecture, University of Kansas Hospital, Kansas City, Kansas, February 24, 1993.

Chronic Lymphocytic Leukemia in the 1990's, Medical Grand Rounds, Barrett Cancer Center, University Hospital, Cincinnati, OH, May 28, 1993.

Overview of Available Cytokines and those in Development, Forum for Advances in Cytokine Therapy, Baylor University Medical, Dallas, TX, June 3, 1993.

Chronic Lymphocytic Leukemia in the 1990's, Medical Grand Rounds, Cooper Hospital, Camden, NJ, June 9, 1993.

Chronic Lymphocytic Leukemia, Medical Grand Rounds, Medical College of Pennsylvania, Philadelphia, PA, June 10, 1993.

Recombinant Human Erythropoietin Therapy in Pre-Dialysis, HIV, and Cancer Patients, Pinellas Pharmacists Society, St. Petersburg, FL, June 10, 1993.

Chronic Lymphocytic Leukemia, Medical Grand Rounds, Rex Hospital Cancer Center, Raleigh, NC, June 15, 1993.

Immunotherapy and Lymphoma, Third Annual Dorothy Inerfield Memorial Symposium, Regional Cancer Foundation, San Francisco, CA, July 10, 1993.

Chronic Lymphocytic Leukemia in the 1990's: An update, Medical Grand Rounds, Erie County Medical Center, Buffalo, NY, July 24, 1993.

Chronic Lymphocytic Leukemia in the 1990's, Medical Grand Rounds, Temple University Comprehensive Cancer Center, Philadelphia, PA, October 4, 1993

Newer Therapies for CTCL: Monoclonal Antibodies, 2nd International Symposium on Cutaneous T-Cell Lymphoma, Northwestern University Medical School, Chicago, IL, October 13, 1993.

Biology and Therapy of Lymphoid Leukemia, Medical Grand Rounds, University of New Mexico Cancer Center, Albuquerque, NM, October 19, 1993.

Combination Therapies in Lymphomas, Third International Symposium on Combination Therapies, Houston, TX, October 29, 1993.

Chair, Hematopoietic Growth Factors and Stem Cells - An Overview, Role of Cytokines in Oncology in the 1990's, Forum for Advances in Cytokine Therapy, Atlanta, GA, November 5, 1993.



Phase I Trial of Anti-Idiotypic Monoclonal Antibody Vaccine Therapy for Patients with Cutaneous T-Cell Lymphoma, American Association for Cancer Research, Inc. Special Conference: Molecular Approaches to Cancer Immunotherapy, Asheville, NC, November 7, 1993.

Session Chair: Therapeutic Applications, Society for Biological Therapy of Cancer VIII, Nashville, TN, November 10, 1993.

Anti-Idiotypic Vaccine Therapy in Cancer, Speaker Series, Duke Comprehensive Cancer Center, Durham, NC, November 19, 1993.

Biology and Therapy of Chronic Lymphoid Leukemia, Speaker Series, Duke Comprehensive Cancer Center, Durham, NC, November 20, 1993.

Transformation of Chronic Lymphocytic Leukemia, International Working Group for Chronic Lymphocytic Leukemia, St. Louis, MO, November 30, 1993.

Mechanisms of Oncogenesis in CLL, Future Directions in Therapy in CLL, International Workshop on Chronic Lymphocytic Leukemia, Wright City, MO, December 1, 1993.

#### International

American Society of Clinical Oncology, May, 1993

Chronic Lymphocytic Leukemia, The American Society of Hematology 35th Annual Meeting and Exposition, "Meet the Professor" session, St. Louis, MO, December 3, 1993.

1994

#### Local

Leukemia, 25th Family Medicine and Primary Care Review, University of Kentucky College of Medicine, Lexington, KY, May 24, 1994.

Leukemias and Lymphomas, Internal Medicine Board Review, University of Kentucky Medical Center, Radisson Plaza, Lexington, KY, July 13, 1994.

Advances in Gene Therapy, Kentucky Cancer Registry, 8th Annual Advanced Cancer Registrars Workshop, Lexington, September 9, 1994.

#### State

Chronic Lymphoid Leukemias - Advances in Biology and Therapy, Medicine Grand Rounds, James Graham Brown Cancer Center, Louisville, KY, May 19, 1994.

National

Chronic Lymphocytic Leukemia in the 1990s: An Update, Grand Rounds Lecture, University of Wisconsin Medical Center, Madison, WI, January 12, 1994.

Epoetin Alpha and 2-CdA: Advances in Clinical Research and Treatment, Faculty Update Symposium, Amelia Island, FL, January 27, 1994.

Biotherapy of Cancer, Medical Grand Rounds, William Beaumont Hospital, Royal Oak, MI, March 2, 1994.

Chronic Lymphocytic Leukemia in the 1990s: An Update, Central Ohio Society of Clinical Oncologists Conference, Columbus, OH, March 15, 1994.

Chronic Lymphocytic Leukemia in the 1990s: An Update, Medical Grand Rounds, St. Luke's Medical Center, Milwaukee, WI, March 31, 1994.

Chronic Lymphoid Leukemia: Recent Advances in Biology and Therapy. 1994 Distinguished Lecture Series, Dayton Oncology Society, Hipple Cancer Center, Dayton, OH, May 6, 1994.

CLL - New Insights in Biology and Therapy, Samuel S. Stratton Veterans Administration Medical Center, Albany, NY, May 12, 1994.

Monoclonals - Therapeutic Applications, St. Vincent's Medical Center, Jacksonville, FL, May 26, 1994.

CLL in the 1990s, Medical Grand Rounds, Roger Williams Medical Center, Providence, RI, May 31, 1994.

CLL in the 1990s: An Update, Medical Grand Rounds, University of South Alabama Medical Center, Mobile, AL, June 9, 1994.

Lymphoid Leukemia - New Concepts in Treatment, Hematology and Medical Oncology Research Conference, Cleveland Clinic, Cleveland, OH, June 24, 1994.

Indolent Non-Hodgkin's Lymphomas, Grand Rounds, Long Island Jewish Medical Center, New Hyde Park, NY, July 14, 1994.

Chronic Lymphoproliferative Disorders: Advances in Biology and Therapy, Medical Grand Rounds, Long Island Jewish Medical Center, New Hyde Park, NY, July 15, 1994.

Non-Hodgkin's Lymphoma, Roche BioScience Meeting, Phoenix, Arizona, September 20, 1994.

New Agents in the Management of Leukemia, Innovative New Therapies in Breast Cancer, Lymphoma and Leukemia Symposium, University Ireland Cancer Center, Cleveland, Ohio, September 21, 1994.

Chronic Lymphocytic Leukemia: New Insights Into Biology and Therapy, Medical Grand Rounds, M. D. Anderson Cancer Center, Houston, September 22, 1994.

Metastatic Melanoma - Current Clinical Management and Future Directions, SWOG Data Managers CE Workshop, Hyatt Regency, San Antonio, October 14, 1994.

Chronic Lymphocytic Leukemia: New Insights Into Biology and Therapy, Hematology/Oncology Grand Rounds, Harper Hospital, Detroit, October 19, 1994.

Monoclonal Antibody Approaches to Cancer Therapy, Third Annual Ingredients for Healing, Oakwood Hospital, Dearborn, MI, October 20, 1994.

#### International

Chronic Lymphoid Leukemias - 1994: Biology, Immunology & Therapy, British Columbia Cancer Agency, Vancouver, B.C., March 18, 1994.

Chronic Lymphocytic Leukemia in the 1990s, Grand Rounds Lecture, Cross Cancer Center, Edmonton, Alberta, March 22, 1994.

Murine Anti-Idiotypic Monoclonal Antibody Induces Specific Humoral Responses to Carcino-Embryonic Antigen in Colorectal Cancer, American Society of Clinical Oncology Annual Meeting, Dallas, TX, May 17, 1994.

Active Immunity to the CEA in Patients Treated with an Anti-Idiotypic Monoclonal Antibody Vaccine. Annual Meeting of Society of Biological Therapy, Silverado Country Club, Napa, CA, October 28-29, 1994.

1995

#### Local

Cancer Center Update, UK Hospital Auxiliary Winter Brunch, Lexington, February 24, 1995.

Cures for Cancer, WVLK Prime Line, Lexington, KY, July 7, 1995.

Leukemias and Lymphomas, Internal Medicine Board Review, University of Kentucky Medical Center, Radisson Plaza, Lexington, KY, July 12, 1995.

Overview of Cancer, Temple Adath Israel, Lexington, KY, September 8, 1995.

Research and New Findings in Breast Cancer, The Thursday Group, Lexington, October 5, 1995.

Strategies for Anti-Cancer Vaccines, American Cancer Society Research Symposium, Lexington, October 21, 1995.

State

The use of immunotherapy with vaccines, Women's Health Festival, Frankfort, September 29, 1995.

National

Anti-idiotypic treatment of cancer, Carolinas Medical Center, Charlotte, NC, April 7, 1995.

Invited presentation, Leukemia Committee, Southwest Oncology Group, Phoenix, AZ, May 1, 1995.

Anti-idiotypic vaccines for cancer therapy, Hem/Onc Grand Rounds, University of Cincinnati, May 12, 1995.

Invited presentation - GI Group, American Society of Clinical Oncology, Los Angeles, May 20, 1995.

Anti-idiotypic antibody vaccines: New prospects in therapy of breast cancer, American Society for Microbiology, Washington, D.C., May 25, 1995.

Flow cytometry from a clinician's perspective, Clinical Cytometry Society, Charleston, SC, August 19, 1995.

CLL - Overview and update on treatment and new strategies, American College of Physicians, Walter Reed Army Medical Center, Reston, VA, October 19, 1995.

International

CLL - Recent advances in Biology and Therapy, Grand Oncology Rounds, Tom Baker Cancer Centre, Alberta, Canada, November 7, 1995.

1996

Local

Overview on lymphoma, Amgen District Meeting, Gratz Park Inn, Lexington, KY, March 6, 1996.

National

Anti-idiotypic vaccine therapy, Lung Committee, Radiation Therapy Oncology Group, New Orleans, LA, February 10, 1996.

Anti-idiotypic monoclonal antibody cancer vaccines, Univ. of Virginia Cancer Center, Charlottesville, VA, March 8, 1996.

Anti-idiotypic vaccines for cancer therapy, Medical Grand Rounds, Roswell Park Cancer Institute, Buffalo, NY, March 22, 1996.

Anti-idiotypic vaccine therapy, Breast, Melanoma, Lung & GI Committees, Southwest Oncology Group, Burlingame, CA, April 28-29, 1996.

Submitted abstract at Joint Meeting of American Society for Biochemistry and Molecular Biology (ASBMB), American Society for Investigative Pathology (ASIP) and American Association of Immunologists (AAI), New Orleans, LA, June 2-6, 1996.

Non-Hodgkin's lymphoma and treatment of low and intermediate grade lymphomas, Regional Medical Symposium, New Orleans, LA, June 12, 1996.

Anti-idiotypic vaccine therapy, Lung Committee, Radiation Therapy Oncology Group, Philadelphia, PA, July 20, 1996.

Diagnosis, recognition and treatment of high-risk melanoma, Quarterly Staff Physicians Meeting, Columbia-Davis Community Hospital, Statesville, NC, July 22, 1996.

Anti-idiotypic vaccine therapy of cancer, Medical Grand Rounds, Wayne State Medical Center, Detroit, MI, July 31, 1996.

Anti-idiotypic vaccine therapy, Scientific Advisory Board, National Surgical Adjuvant Breast and Bowel Project, Palm Beach, FL, September 25, 1996.

Immune flow cytometry: application to the diagnosis of lymphoma, Jaffar Annual Oncology Conference, Providence Cancer Center, Southfield, MI, September 27, 1996.

Anti-idiotypic antibody vaccines that mimic CEA for patients with colorectal cancer, National Surgical Adjuvant Bowel and Breast Project Investigators Meeting, Baltimore, MD, November 8-9, 1996.

Anti-idiotypic monoclonal antibodies that mimic the GD2 ganglioside and CEA, Melanoma/Sarcoma Staff Research Seminar, MD Anderson Cancer Center, Houston, TX, December 2, 1996.

Therapy of patients with anti-idiotypic monoclonal antibody that mimics CEA, Cell Biology Program of Molecular Therapy Seminar Series, MD Anderson Cancer Center, Houston, TX, December 3, 1996.

### International

Anti-idiotypic antibody vaccine, American Society of Clinical Oncology Annual Meeting, Philadelphia, PA, May 20, 1996.

Anti-idiotypic vaccine (3H1) that mimics the carcinoembryonic antigen (CEA), The Seventh International CEA/PSG Workshop, Duarte, CA, September 15, 1996.

Anti-idiotypic antibody vaccine (3H1) that mimics the carcinoembryonic antigen (CEA), Third International Conference on Engineered Vaccines for Cancer and AIDS, Cambridge Symposia, Hilton Head Island, SC, October 12, 1996.

1997

National

Anti-idiotypic vaccine therapy of cancer, Arkansas Cancer Research Center Seminar, Little Rock, AR, January 12, 1997.

Lymphoproliferative disorders, Southwestern Oncology Group (SWOG) Annual Meeting, Dallas TX, April 3, 1997.

Immunobiology and biologic therapy in Curran B, American Society of Clinical Oncology (ASCO), Denver, CO, May 19, 1997.

Anti-idiotypic vaccine therapy for colorectal cancer, Garden State Cancer Center, Lyndhurst, NJ, June 9, 1997.

Induction of antitumor immunity by an anti-idiotypic antibody mimicking carcinoembryonic antigen, National Surgical Adjuvant Bowel and Breast Project Colorectal Committee Meeting, June 17, 1997.

Monoclonal Antibody Treatment - Colon Cancer, Stevens Cancer Center Symposium, The Scripps Clinic, La Jolla, CA, October 16, 1997.

Anti-idiotypic vaccine therapy for colorectal cancer, University of South Carolina School of Medicine, Columbia, South Carolina, October 31, 1997.

Anti-idiotypic vaccine therapy for malignant melanoma, Tumor Conference, Comprehensive Cancer Research Group, Salick Health Care, Miami, Florida, November 12, 1997.

Anti-idiotypic vaccine therapy for breast cancer, CALGB Fall Group Meeting, University of Chicago, Orlando, Florida, November 22, 1997.

Anti-idiotypic vaccine therapy for colorectal cancer, Cancer Institute of New Jersey, New Brunswick, New Jersey, December 17, 1997.

1998

Local

Management of low grade lymphoma, Emerging Trends in the Treatment of Lymphoma, Continuing Medical Education Program, Hilton Suites of Lexington Green, Lexington, Kentucky, June 13, 1998.

National

Anti-idiotypic vaccine that mimics the carcinoembryonic antigen, Albert Einstein College, Bronx, New York, January 29, 1998.

Immunotherapy for Colon Cancer (CEA Idiotypic), Regional Cancer Center Consortium for Biological Therapy of Cancer, Buffalo, New York, February 21, 1998.

Anti-idiotypic vaccine therapy of colorectal cancer targeting the carcinoembryonic antigen, University of Cincinnati, Barrett Cancer Center, Cincinnati, Ohio, March 16, 1998.

Monoclonal antibodies for cancer therapy, Oncology Symposium, Carl & Dorothy Bennett Cancer Center, Stamford Hospital, Stamford, Connecticut, April 22, 1998.

Anti-idiotypic vaccine therapy of colorectal cancer mimicking CEA, Grand Rounds Series, Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Research Institute, Columbus, Ohio, April 24, 1998.

Idiotypic vaccines for colorectal cancer, Vaccine Research Workshop, Southwest Oncology Group Meeting (SWOG), Atlanta, Georgia, April 24, 1998.

Immune responses in advanced melanoma patients immunized with an anti-idiotypic (Id) antibody mimicking disialoganglioside GD2. American Society of Clinical Oncology (ASCO), Los Angeles, CA, May 18, 1998.

Clinical and immune responses in surgically resected colorectal cancer (CRC) patients treated with an anti-idiotypic (Id) monoclonal antibody that mimics carcinoembryonic antigen (CEA) with or without 5-fluorouracil (5-FU). American Society of Clinical Oncology (ASCO), Los Angeles, CA, May 18, 1998.

Immune responses in patients with breast cancer treated with an anti-idiotypic antibody that mimics the human milk fat globule (HMFG) antigen. American Society of Clinical Oncology (ASCO), Los Angeles, CA, May 18, 1998.

Immune phenotype of lymphomas and leukemias, Huntington Blood Club, Marshall University, Department of Medicine, Huntington, West Virginia, June 1, 1998.

Classification of lymphomas and novel new therapies, Medical Grand Rounds, Cabell Huntington Hospital, Marshall University, Huntington, West Virginia, June 2, 1998.

Phase II study of Doxil in the treatment of patients with refractory/relapsed NHL, Doxil Advisory Panel Meeting, Ritz-Carlton Amelia Island, Florida, June 6, 1998.

Novel antibody therapies for cancer, Medical Grand Rounds, Rush Presbyterian St. Lukes Medical Center, Chicago, Illinois, June 24, 1998.

Novel approaches to antibody therapy for cancer, Dinner Lecture, Akron General Cancer Center, Akron, Ohio, June 30, 1998.

Anti-idiotypic monoclonal antibody vaccine that mimics the carcinoembryonic antigen: The novel therapeutic approach to colorectal cancer, Cancer Therapy Research Center Burton & Miriam Grossman, San Antonio, Texas, August 13, 1998.

Novel new antibody approaches to cancer therapy, Tumor Board, Community Hospital East, Indianapolis, Indiana, September 22, 1998.

Cancer vaccines, Oncology Program, Akron General Medical Center, Akron, Ohio, October 14, 1998.

Anti-idiotypic antibody vaccine mimicking carcinoembryonic antigen, Chemotherapy Foundation Symposium XVI Innovative Cancer Therapy for Tomorrow, Mount Sinai School of Medicine, New York, New York, November 11, 1998.

Anti-idiotypic vaccine that mimics CEA for therapy of colon cancer, ECOG GI Committee, Northwestern University Medical School, Miami, Florida, November 21, 1998.

Excellent responses to sequential fludarabine (F) followed by cyclophosphamide (C), mitoxantrone (M), vincristine (V), and prednisone (P) (CNOP) in previously untreated patients with follicle center lymphoma, grade I and II, The 40<sup>th</sup> Annual Meeting of the American Society of Hematology, Miami, Florida, December 7, 1998.

### International

Clinical and immune responses in colorectal cancer (CRC) patients treated with an anti-idiotypic (Id) monoclonal antibody (mAb) that mimics carcinoembryonic antigen (CEA), XVII International Cancer Congress, Rio de Janeiro, Brazil, August 24-28, 1998.

1999

### Local

Anti-Idiotypic Vaccine Approach to the Treatment of Colorectal Cancer, Medicine Grand Rounds, University of Cincinnati, Cincinnati, OH, February 24, 1999.

Vaccine Approaches to the Treatment of Colorectal Cancer, Environmental Health Seminar, University of Cincinnati College of Medicine, Cincinnati, OH, April 14, 1999.

Anti-Idiotypic Vaccine Approach to Cancer, Head & Neck Cancer: Conference, the Barrett Cancer Center, University of Cincinnati, Cincinnati, OH, June 19, 1999.



Cancer Research Update, Focus Research Breakfast, The University of Cincinnati Foundation, Cincinnati, OH, June 23, 1999.

Future Direction for Cancer Research at the Barrett Cancer Center, American Cancer Society Research Reception, Cincinnati, OH, September 16, 1999.

Anti-Idiotypic Antibody Vaccines: Novel Approach to Cancer Immunotherapy, Molecular to the Bedside, University of Cincinnati College of Medicine, Cincinnati, OH, September 30, 1999.

Monoclonal Antibody Anti-Idiotypic Vaccine Therapy, Hematology-Oncology Grand Rounds, University of Cincinnati, Cincinnati, OH, October 1, 1999.

New Approaches to the Treatment of Lymphoma, Cincinnati Society of Internal Medicine, University of Cincinnati, Cincinnati, OH, October 4, 1999.

Anti-Idiotypic Vaccine Therapy of Melanoma, University of Cincinnati, Cincinnati, OH, The Barrett Cancer Center, October 26, 1999.

Lymphoma, Wellness Community, Cincinnati, OH, November 6, 1999.

Ensuring Quality Cancer Care, The Central Ohio River Valley Cancer Alliance, Cincinnati, OH, November 30, 1999.

#### National

Breast Cancer: Clinical Issues, International Cancer Alliance Breast Cancer Symposium, West Palm Beach, FL, January 23, 1999.

Immunologic Approaches to Malignant Melanoma, First Annual International Melanoma Conference, Miami Beach, FL, February 13, 1999.

Monoclonal Antibodies in the Treatment of Breast Cancer, 22<sup>nd</sup> Annual Gold Coast Conference: Breast Cancer, West Palm Beach, FL, February 23, 1999.

Anti-Idiotypic Vaccines: Novel Approach for the Therapy of Colorectal Cancer, Annual Cancer Conference, Swedish Medical Center, Seattle, WA, April 23, 1999.

Colorectal Cancer as a Model for Immunotherapy, Southwest Oncology Group Conference, Phoenix, AZ, April 28 – May 2, 1999.

Anti-Idiotypic Antibody Vaccines, Targeted Cellular Toxicity: The VIth International Conference on Bispecific Antibodies Conference, Asilomar Conference Center, Pacific Grove, CA, July 30, 1999.

Targeted Therapies in the Treatment of Lymphoma, University of Louisville, Louisville, KY, August 5, 1999.

Lymphoma, Educational Overview, SuperGen Meeting, Phoenix, AZ, August 16, 1999.

Anti-Idiotypic Monoclonal Antibody Vaccine that Mimics the Carcinoembryonic Antigen, 12<sup>th</sup> International Conference on Monoclonal Antibody Immunoconjugates for Cancer, San Diego, CA, October 14 – 16, 1999.

2000

Local

Anti-Idiotypic Cancer Vaccines, The Children's Hospital Research Foundation Immunotherapy Conference, Cincinnati, OH, January 31, 2000.

Anti-idiotypic Vaccine that Mimics CEA: Novel therapeutic approach to colon cancer treatment. Case Western University, Ireland Cancer Center, Blood Club Seminar, Cleveland, OH, February 25, 2000.

The Barrett Cancer Center in the New Millennium. UC Board of Trustees, University of Cincinnati, Cincinnati March 29, 2000.

Anti-idiotypic Vaccine that Mimics the Carcinoembryonic Antigen. Dept. of Pathology and Laboratory Medicine, University of Cincinnati, Cincinnati, OH April 20, 2000.

Cancer Vaccines. Sabin 40<sup>th</sup> Annual Anniversary Celebration, University of Cincinnati, Cincinnati, OH April 28, 2000.

The Barrett Cancer Center and the New Millennium. UC Medical Center Orientation, Cincinnati, OH May 4, 2000.

Non-Hodgkin's Lymphoma. Miami Valley Hospital Tumor Board, Dayton, OH May 5, 2000.

Colorectal Cancer: Molecular Genetics and Therapeutic Advances. University-Wide Clinical Pathology Conference, Cincinnati, OH May 10, 2000.

Vaccine Therapies of Malignant Melanoma. Hematology-Oncology Grand Rounds, University of Cincinnati, Cincinnati, OH. May 26, 2000.

Welcome and Introduction, Cancer Survivor's Day, University of Cincinnati, Cincinnati, OH, June 4, 2000.

Vaccine Approaches to the Adjuvant Treatment of Colorectal Cancer. The Barrett Cancer Center and University of Cincinnati Annual Cancer Conference. Cincinnati, OH June 17, 2000.

Chronic Lymphoid Leukemias. Hematology-Oncology Grand Rounds Conference, University of Cincinnati, Cincinnati, OH. September 29, 2000.

Overview of Immune Flow Cytometry of Leukemias and Lymphomas. The Barrett Cancer Center, University of Cincinnati College of Medicine, Cincinnati, OH. October 7, 2000.

### National

Anti-Idiotypic Antibodies Directed Against Gangliosides. Melanoma at the Millennium Conference, Phoenix, AZ, February 17, 2000

Clinical and Immune Responses in Resected Colon Cancer patients Treated with Anti-Idiotypic Monoclonal Antibody Vaccine that mimics the Carcinoembryonic Antigen. International Conference on Advances in Cancer Immunotherapy, Princeton, NJ, March 2 - 4, 2000.

Clinical Trials of Immunotherapeutics and Immunologic Monitoring. American Association for Cancer Research, April 3 - 4, 2000.

Cancer Vaccines. 2000 American Society of Clinical Oncology, New Orleans, LA. May 19 - 22, 2000.

An Update on Cancer Vaccines. 12<sup>th</sup> Annual Western North Carolina Cancer Conference, Asheville, North Carolina, October 27, 2000.

Rubitecan: An Effective New Therapy in Pancreatic Cancer. Chemotherapy Foundation Symposium XVIII, New York City, New York, November 8, 2000.

Vaccine in the Treatment of GI Malignancies. Gastrointestinal Cancer Research Conference 2000, Orlando, Florida, November 16 - 18, 2000.

### International

Clinical and immune responses in resected colon cancer patients treated with anti-idiotypic monoclonal antibody vaccine that mimics the carcinoembryonic antigen. 2<sup>nd</sup> Annual Walker's Cay Colloquium, Albert B. Sabin Vaccine Institute, Abaco, Bahamas, March 8 - 12, 2000.

2001

### Local

### National

Anti-Idiotypic Antibody that Mimics Carcinoembryonic Antigen: Novel new Approach to Colon Cancer Immunotherapy. The Molecular Medicine of Colorectal Cancer, Keystone Symposia on Molecular and Cellular Biology, Taos, New Mexico, February 1 - 2, 2001.

Expanding Options in the Treatment of Non-Hodgkin's Lymphoma. Medical City Tumor Conference, Medical City Dallas Hospital, Dallas, TX. March 21, 2001.

Monoclonal Antibodies in Combination with Chemotherapy for the Treatment of Non-Hodgkin's Lymphoma. IDEC Pharmaceuticals Corporation, Dallas, TX. March 21, 2001.

CeaVac, a Novel Anti-Idiotypic Antibody Vaccine Therapy for Colon Cancer. American Cancer Society, 43<sup>rd</sup> Annual Science Writers Seminar, Laguna Beach, CA. April 22 – 25, 2001.

### International

## XIV. RESEARCH AND/OR CREATIVE PRODUCTIVITY

### 1. Publications

#### *A. Peer-Reviewed Manuscripts:*

1. Foon KA, Wahl SM, Oppenheim JJ and Rosenstreich DL: Serotonin-induced production of a monocy
2. Sher NA, Foon KA, Fishman ML and Brown T: Demonstration of monocyte chemotactic factors in the aqueous humor during experimental immunogenic uveitis in the rabbit. *Infect Immun* 13:1110-1116, 1976.
3. Sher ND, Douglas DJ, Mindrup E, Minaii LA and Foon KA: Macrophage migration inhibition factor activity in the aqueous humor during experimental corneal xenograft and allograft rejection. *Am J Ophthalmol* 82:858-865, 1976.
4. Foon KA, Yuen K, Ballintine E and Rosenstreich D: Analysis of the systemic corticosteroid sensitivity of patients with primary open angle glaucoma. *Am J Ophthalmol* 83:167-173, 1977.
5. Foon KA, Naiem F, Yale C and Gale RP: Acute myelogenous leukemia: Morphologic subclass and response to therapy. *Leuk Res* 3:171-173, 1979.
6. Foon KA, Billing RJ and Terasaki PI: Dual B and T markers in acute and chronic lymphocytic leukemia. *Blood* 55:16-20, 1980.
7. Billing RJ, Clark BM, Koeffler P, Foon KA and Terasaki PI: Acute myelocytic leukemia heteroantisera. *Clin Immunol Immunopathol* 16:202-210, 1980.
8. Foon KA, Yale C, Clodfelter K and Gale RP: Effect of posttreatment hepatitis on survival of patients with acute myelogenous leukemia. *JAMA*, 244:1806-1807, 1980.
9. Foon KA, Fitchen JH, Billing RJ, Belzer MB, Terasaki PI and Cline MJ: An antithymocyte serum non-cytotoxic to myeloid progenitor cells: Candidate serum for prevention of graft-versus-host disease in bone marrow transplantation. *Clin Immunol Immunopathol* 16:416-422, 1980.

10. Foon KA, Billing RJ, Terasaki PI and Cline MJ: Immunologic classification of acute lymphocytic leukemia: Implications for normal lymphoid differentiation. *Blood* 56:1120-1126, 1980.
11. Foon KA, Herzog P, Billing R, Terasaki PI and Feig S: Immunologic classification of childhood acute lymphocytic leukemia. *Cancer* 47:280-284, 1981.
12. Foon KA, Naeim F, Saxon A, Stevens R and Gale RP: Leukemia of T-helper lymphocytes: Clinical and functional characterization. *Leuk Res* 5:1-10, 1981.
13. Foon KA, Billing RJ, Fitchen JH, Belzer MB, Drew SI and Terasaki PI: An antigen expressed by cells of the myelo-monocytic lineage. *Am J Hematol* 10:259-267, 1981.
14. Belzer M, Fitchen JH, Ferrone S, Foon KA, Billing RJ and Golde DW: Expression of HLA-DR antigen on human erythroid progenitor cells as determined by monoclonal anti-DR antibodies and heteroantiserum. *Clin Immunol Immunopathol* 20:111-115, 1981.
15. Gale RP, Foon KA, Cline MJ and Zighelboim J: Intensive chemotherapy for acute myelogenous leukemia. *Ann Intern Med* 94:753-757, 1981.
16. Fitchen JH, Foon KA and Cline MJ: The antigenic characteristics of hematopoietic stem cells. *N Engl J Med* 305:17-25, 1981.
17. Foon KA, Zighelboim J, Yale C and Gale RP: Intensive chemotherapy is the treatment of choice for elderly patients with acute myelogenous leukemia. *Blood* 58:467-470, 1981.
18. Foon KA, Filderman A and Gale RP: Histiocytic lymphoma following resolution of sarcoidosis. *Med Pediatr Oncol* 9:325-331, 1981.
19. Hoffman F, Foon KA, Smith D, Kransler J, Ciciarelli J and Billing R: Functional properties of subsets of T lymphocytes defined by special antigens. *Clin Exp Immunol* 44:476-484, 1981.
20. Hocking WG, Billing R.J, Foon KA and Golde DW: Human alveolar macrophages express DR antigens. *Blood* 58:1040-1042, 1981.
21. Linker-Israeli M, Billing RJ, Foon KA and Terasaki PI: Monoclonal antibodies reactive with acute myelogenous leukemia cells. *J Immunol* 127:2473-2477, 1981.
22. Billing R, Terasaki PI, Sugich L and Foon KA: Detection of differentiation antigens by use of monoclonal antibodies. *J Immunol Methods* 47:289-294, 1981.
23. Schroff RW, Foon KA, Billing RJ and Fahey JL: Immunologic classification of lymphocytic leukemias based on monoclonal antibody-defined cell surface antigens. *Blood* 59:207-215, 1982.

24. Foon KA and Haskell CM: Inadvertent overdose with lomustine (CCNU) followed by hematologic recovery. *Cancer Treat Reports* 66:1241-1241, 1982.
25. Foon KA and Gale RP: Controversies in the therapy of acute myelogenous leukemia. *Am J Med* 72:963-979, 1982.
26. Foon KA, Schroff RW and Gale RP: Cell surface markers on leukemia and lymphoma cells: Recent advances. *Blood* 60:1-19, 1982.
27. Billing RJ, Foon KA and Linker-Israeli M: The immunological classification of leukemia based on a rapid microcytotoxicity test. *Clin Exp Immunol* 49:142-148, 1982.
28. Schroff RW and Foon KA: Heterogeneity in a lymphoid tumor: Co-expression of T and B surface markers. *Blood* 60:373-380, 1982.
29. Foon KA, Schroff RW and Fliegel S: Monoclonal antibody characterization of plasmacytoma cells associated with T lymphocytes with a suppressor phenotype. *Clin Immunol Immunopathol* 25:59-66, 1982.
30. Foon KA, Bernhard MI and Oldham RK: Monoclonal antibody therapy: Assessment by animal tumor models. *J Biol Response Mod* 1:277-304, 1982.
31. Sherwin SA, Knost JA, Fein S, Abrams PG, Foon KA, Ochs JJ, Schoenberger C, Maluish AE and Oldham RK: A multiple dose phase I trial of recombinant leukocyte A interferon in cancer patients. *JAMA* 248:2461-2466, 1982.
32. Key ME, Bernhard MI, Hoyer LC, Foon KA, Oldham RK and Hanna MG: Guinea pig line 10 hepatocarcinoma model for monoclonal antibody serotherapy: *In vivo* localization of a monoclonal antibody in normal and malignant tissues. *J Immunol* 120:1451-1457, 1983.
33. Sherwin SA, Mayer D, Ochs JJ, Abrams PG, Knost JA, Foon KA, Fein S and Oldham RK: Recombinant leukocyte A interferon in advanced breast cancer: Results of a Phase II efficacy trial. *Ann Intern Med* 98:598-602 1983.
34. Bernhard MI, Foon KA, Oeltmann TN, Key ME, Hwang KM, Clarke CG, Christensen WL, Hoyer LC, Hanna MG and Oldham RK: Guinea pig line 10 hepatocarcinoma model: Characterization of monoclonal antibody and *in vivo* effect of unconjugated antibody and antibody conjugated to diphtheria toxin A chain. *Cancer Res* 43:4420-4428, 1983.
35. Bernhard MI, Hwang KM, Foon KA, Keenan A, Kessler R, Frincke, Tallum DJ, Hanna MG, Peters L and Oldham RK: Localization of <sup>111</sup>In- and <sup>125</sup>Io-labeled monoclonal antibody in guinea pigs bearing line 10 hepatocarcinoma tumors. *Cancer Res* 43:4429-4433, 1983.
36. Foon KA, Smalley RV, Riggs CW and Gale RP: The role of immunotherapy in acute myelogenous leukemia. *Arch Intern Med* 143:1726-1734, 1983.

37. Knost JA, Sherwin SA, Abrams PG, Ochs JJ, Foon KA, Williams R, Tuttle R and Oldham RK: The treatment of cancer patients with human lymphoblastoid interferon: A comparison of two routes of administration. *Cancer Immunol Immunother* 15:148-155, 1983.
38. Abrams PG, Knost JA, Clarke G, Wilburn S, Oldham RK and Foon KA: Determination of the optimal human cell lines for development of human hybridomas. *J Immunol* 131:1201-1204, 1983.
39. Foon KA, Buescher S, Kimball ES, Huang LC, Stevenson HC, Clarke G, Gregoria T and Harley JB: Monoclonal antibody to human eosinophils recognizing 95 kD surface membrane antigen. *Hybridoma* 2:393-402, 1983.
40. Stevenson HC, Foon KA, Kanapa DJ, Favilla T, Beman J and Oldham RK: The potential value of cytopheresis for adoptive immunotherapy of cancer patients. *Plasma Ther Transfus Technol* 5:237-250, 1984.
41. Hwang JM, Foon KA, Cheung PH, Pearson JW and Oldham RK: Selective antitumor effect on L10 hepatocarcinoma cells of a potent immunoconjugate composed of the A chain of abrin and a monoclonal antibody to a hepatoma-associated antigen. *Cancer Res* 44:4578-4586, 1984.
42. Foon KA, Mutsuyasu RT, Schroff RW, McIntyre RE, Champlin R and Gale RP: Immune deficiency in young males with hepatitis-associated severe aplastic anemia. *Ann Intern Med* 100:657-662, 1984.
43. Oldham RK, Morgan AC, Woodhouse CS, Schroff RW, Abrams PG and Foon KA: Monoclonal antibodies in the treatment of cancer: Preliminary observations and future prospects. *Med Oncol Tumor Pharmacother* 1:51-62, 1984.
44. Abrams PG, Ochs JJ, Giardina SL, Morgan AC, Wilburn SB, Wilt AR, Oldham RK and Foon KA: Production of large quantities of human immunoglobulin in the ascites of athymic mice: Implication for the development of anti-human idiotype monoclonal antibodies. *J Immunol* 132:1611-1613, 1984.
45. Stevenson HC, Ochs JJ, Halverson L, Oldham RK, Sherwin SA and Foon KA: Recombinant alpha interferon in retreatment of two patients with pulmonary lymphoma. Dramatic responses with resolution of pulmonary complications. *Am J Med* 77:355-358, 1984.
46. Fer MF, Beman J, Stevenson HC, Maluish A, Moratz C, Foon KA, Herberman RB, Oldham RK, Terman DS, Young JB and Daskal Y: A trial of autologous plasma perfusion over protein A in patients with breast cancer. *J Biol Response Mod* 3:352-358, 1984.
47. Champlin R, Jacobs A, Gale RP, Boccia R, Elashoff R, Foon KA and Zighelboim J: Prolonged survival in acute myelogenous leukemia without maintenance chemotherapy. *Lancet* 1:894-896, 1984.

48. Schroff RW, Farrell MM, Klein RA, Oldham RK and Foon KA: T65 antigen modulation in a phase I monoclonal antibody trial with chronic lymphocytic leukemia patients. *J Immunol* 133:1641-1648, 1984.
49. Foon KA, Neubauer RH, Wikstrand CJ, Schroff RW, Rabin H and Seeger RC: Human Thy-1 antigen: Distribution on human and non-human primate hematopoietic cells. *J Immunogenet* 11:233-244, 1984.
50. Foon KA, Schroff RW, Bunn RA, Mayer D, Abrams PG, Fer MF, Ochs JJ, Bottino GC, Sherwin SA, Herberman RB and Oldham RK: Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia. *Blood* 64:1085-1094, 1984.
51. Oldham RK, Foon KA, Morgan AC, Woodhouse C, Schroff RW, Abrams PG, Fer MF, Schoenberger C, Farrell M, Kimball E and Sherwin SA: Monoclonal antibody therapy of malignant melanoma: *In vivo* localization in cutaneous metastasis after intravenous administration. *J Clin Oncol* 2:1235-1244, 1984.
52. Reynolds CW and Foon KA: T-lymphoproliferative disease and related disorders in man and experimental animals. A review of the clinical, cellular and functional characteristics. *Blood* 64:1146-1158, 1984.
53. Fer MF, Bottino GC, Sherwin SA, Hainesworth JD, Abrams PG, Foon KA and Oldham, RK: Atypical tumor lysis syndrome in a patient with T-cell lymphoma following recombinant interferon therapy. *Am J Med* 77:953-956, 1984.
54. Bunn PA, Foon KA, Idhe DC, Winkler CF, Zeffren J, Sherwin SA and Oldham RK: Recombinant leukocyte A interferon: An active agent in advanced cutaneous T-cell lymphoma. *Ann Intern Med* 101:484-487, 1984.
55. Stevenson HC, Kimball ES, Buescher S, Clarke G and Foon KA: Monoclonal antibody to human monocytes and granulocytes: Isolation of membrane antigens and lack of effect on leukocyte functions *in vitro*. *Hybridoma* 3:247-261, 1984.
56. Foon KA, Sherwin SA, Abrams PG, Longo DL, Fer MF, Stevenson HC, Ochs JJ, Bottino GC, Schoenberger CS, Zeffren J, Jaffe ES and Oldham RK: Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon. *N Engl J Med* 311:1148-1152, 1984.
57. Morgan AC, Woodhouse CS, Knost JA, Abrams PG, Clarke GC, Arthur LO, McIntyre R, Ochs JJ, Foon KA, Hanna MG and Oldham RK: Monoclonal antibodies to human colorectal tumor-associated antigens: Improved elicitation and subclass restriction. *Hybridoma* 3:233-245, 1984.
58. Sherwin SA, Foon KA, Oldham RK, Abrams PG, Heyman MR, Ochs JJ, Watson R and Maluish A: A preliminary phase I trial of partially purified interferon-gamma (IFN-gamma) in patients with disseminated cancer. *Biol Response Mod* 3:599-607, 1984.



59. Bunn PA, Carrasquillo JA, Keenan AM, Schroff RW, Foon KA, Hsu SM, Gazdar AF, Reynolds JJ, Perentesis P and Larson SM: Imaging of T-cell lymphoma by radiolabeled monoclonal antibody. *Lancet* 1219-1221, 1984.
60. Wei N and Foon KA: Sclerodactyly in a patient with mycosis fungoides. *Arch Intern Med* 145:139-140 1985.
61. Schroff RW, Foon KA, Wilburn SB, Oldham RK and Morgan AC: Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. *Cancer Res* 45:879-885, 1985.
62. Schroff RW, Woodhouse CS, Foon KA, Farrell MM, Klein RA, Oldham RK and Morgan AC: Intratumor localization of monoclonal antibody in patients with melanoma treated with antibody to a 250,000-dalton melanoma-associated antigen. *J Natl Cancer Inst* 74:299-306, 1985.
63. Foon KA, Bottino GC, Abrams PG, Fer MF, Longo DL, Schoenberger CS and Oldham RK: A phase II trial of recombinant leukocyte A interferon for patients with advanced chronic lymphocytic leukemia. *Am J Med* 78:216-220, 1985.
64. Gale RP and Foon KA: Chronic lymphocytic leukemia: Recent advances in biology and treatment. *Ann Intern Med* 103:101-120, 1985.
65. Giardina SL, Schroff RW, Woodhouse CS, Golde DW, Oldham RK, Cleary ML, Sklar J, Pritikin N and Foon KA: Detection of two malignant B-cell clones in a single patient using anti-idiotypic monoclonal antibodies and immunoglobulin gene rearrangement. *Blood* 66:1017-1021, 1985.
66. Giardina SL, Schroff RW, Kipps TJ, Woodhouse CS, Abrams PG, Rager HC, Morgan AC and Foon KA: The generation of monoclonal anti-idiotypic antibodies to human B-cell derived leukemias and lymphomas. *J Immunol* 135:653-658, 1985.
67. Foon KA, Rossio JL, Schroff RW, Wahl SM, Abrams PG, Rager HC, Pickeral SF and Fidler IJ: The generation of stable human T-cell hybridomas which constitutively produce interleukin-2 and chemotactic factor. *Hybridoma* 4:211-222, 1985.
68. Stevenson HC, Abrams PG, Schoenberger CS, Smalley RV, Herberman RB and Foon KA: A phase I evaluation of poly ICLC in cancer patients. *J Biol Response Mod* 4:650-655, 1985.
69. Foon KA, Sherwin SA, Abrams PG, Stevenson HC, Holmes P, Maluish AE, Oldham RK and Herberman RB: A phase I trial of recombinant gamma interferon in patients with cancer. *Cancer Immunol Immunother* 20:193-197, 1985.

70. Maluish AE, Reid JW, Crisp EA, Overton WR, Levy H, Foon KA and Herberman RB: Immunomodulatory effects of Poly(I,C)-LC in cancer patients. *J Biol Response Mod* 4:656-663, 1985.
71. Foon KA, Maluish AE, Abrams PG, Wrightington S, Stevenson HC, Alarif A, Fer MF, Overton WR, Poole M, Schnipper EF, Jaffe ES and Herberman RB: Recombinant leukocyte A interferon therapy for advanced hairy cell leukemia: Therapeutic and immunologic results. *Am J Med* 80:351-356, 1986.
72. Bunn PA Jr, Ihde DC and Foon KA: The role of recombinant leukocyte A interferon in the therapy of cutaneous T-cell lymphomas. *Cancer* 57:1315-1321, 1986.
73. Foon KA and Todd RF III: Immunologic classification of leukemia and lymphoma. *Blood* 68:1-31, 1986.
74. Giardina SL, Foon KA, Beatty SM and Morgan AC Jr: Evaluation of alternative methodologies for the generation of monoclonal anti-idiotypic antibodies to human B-cell derived leukemias and lymphomas. *J Immunol Methods* 89:1-7, 1986.
75. Faltynek CR, Princler GL, Ruscetti FW, Maluish AE, Abrams PG and Foon KA: Relationship of the clinical response and binding of recombinant interferon alpha in patients with lymphoproliferative diseases. *Blood* 68:297-300, 1986.
76. Foon KA, Nakano GM, Koller CA, Longo DL and Steis RG: Response to 2'-deoxycoformycin after failure of interferon alpha in non-splenectomized patients with hairy cell leukemia. *Blood* 68:297-300, 1986.
77. Roth MS and Foon KA: Alpha interferon in the treatment of hematologic malignancies. *Am J Med* 81:871-882, 1986.
78. Carrasquillo JA, Bunn PA Jr, Keenan AM, Reynolds JC, Schroff RW, Foon KA, Ming-Hsu S, Gazdar AR, Mulshine JL, Oldham RK, Perentesis P, Horowitz M, Eddy J, James P and Larson SM: Radio-immunodetection of cutaneous T-cell lymphoma with <sup>111</sup>In-T101 monoclonal antibody. *N Engl J Med* 315:673-680, 1986.
79. Carrasquillo JA, Mulshine JL, Bunn PA, Reynolds JC, Foon KA, Schroff RW, Perentesis P, Steis RG, Keenan AM, Horowitz M and Larson SM: Tumor imaging of <sup>111</sup>In T-101 monoclonal antibody is superior to <sup>131</sup>I T-101 in cutaneous T-cell lymphoma. *J Nucl Med* 28:281-287, 1987.
80. Schroff RW, Morgan AC, Woodhouse CS, Abrams PG, Farrell MM, Carpenter BE, Oldham RK and Foon KA: Monoclonal antibody therapy in malignant melanoma: Factors effecting *in vivo* localization. *J Biol Response Mod* 6:457-472, 1987.
81. Kahn P, Roth MS, Keren DF and Foon KA: Light chain disease associated with the hyperviscosity syndrome. *Cancer* 60:2267-2268, 1987.

82. Eger RR, Covell DG, Carrasquillo JA, Abrams PG, Foon KA, Reynolds JC, Schroff RW, Morgan AC, Larson SM and Weinstein JN: Kinetic model for the biodistribution of an  $^{111}\text{In}$ -labeled monoclonal antibody in humans. *Cancer Res* 47:1-9 1987.
83. Stevenson HC, Keenan AM, Woodhouse C, Ottow RT, Miller P, Stellar EP, Foon KA, Abrams PG, Beman J, Larsen SM and Sugarbaker PH: Fate of gamma-interferon-activated killer blood monocytes adoptively transferred into the abdominal cavity of patients with peritoneal carcinomatosis. *Cancer Res* 47:6100-6103, 1987.
84. Keenan AM, Weinstein JN, Carrasquillo JA, Bunn PA Jr, Reynolds JC, Foon KA, et al: Immunolymphoscintigraphy and the dose-dependence of Indium $^{111}$  labeled T-101 monoclonal antibody in patients with cutaneous T-cell lymphoma. *Cancer Res* 47:6093-6097, 1987.
85. Carrasquillo JA, Abrams P, Schroff R, Reynolds J, Morgan C, Keenan A, Foon KA, Perentesis P, Marshall S, Horowitz M, Szimendera J, Oldham R and Larson SM: Effect of  $^{111}\text{In}$ -9.2.27 monoclonal antibody dose on the imaging of metastatic melanoma. *J Nucl Med* 29:39-47 1988.
86. Second MIC Cooperative Study Group. Morphologic, immunologic and cytogenetic (MIC) working classification of the acute myeloid leukemias. *Cancer Genet Cytogenet* 30:1-15, 1988.
87. Buchsbaum DJ, Sinkule JA, Stites MS, Fodor PA, Hanna DE, Ford SM, Warber-Matich SL, June JE and Foon KA: Localization and imaging with radioiodine-labeled monoclonal antibodies in xenogeneic tumor model for human B-cell lymphomas. *Cancer Res* 48:2475-2482, 1988.
88. Gale RP and Foon KA: Daunorubicin or doxorubicin in acute myelogenous leukemia? *Leukemia* 2:209-210, 1988.
89. Third MIC Cooperative Study Group: Recommendations for a morphologic, immunologic and cytogenetic (MIC) working classification of the primary and therapy-related myelodysplastic disorders. *Cancer Genet Cytogenet* 32:1-10, 1988.
90. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia: Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized controlled clinical trial. *N Engl J Med* 319:902-907, 1988.
91. Cheson BD, Bennett JM, Rai KR, Greaves MR, Kay NE, Schiffer CA, Keating MJ, Kempin SJ, Boldt DH and Foon KA: Guidelines for clinical protocols for chronic lymphocytic leukemia (CLL): Recommendations of the NCI-sponsored working group. *Am J Hematol* 29:152-163, 1988.

92. Foon KA, Doroshow J, Bonnem E, Fefer A, Graham S, Grosh B, Narayan P, Elias L, Harvey H, Schulof R, Williams R, Rinehart J, Zekan P, Catalona W, Dillman R, Salmon S and Galasso F: A prospective randomized trial of alpha 2B-interferon/gamma-interferon or the combination in advanced metastatic renal cell carcinoma. *J Biol Response Mod* 7:540-545, 1988.
93. Foon KA: Biological response modifiers: The new immunotherapy. *Cancer Res* 49:1621-1639 1989.
94. Biddle W, Pancook J, Foon KA, Goldrosen M and Vaickus L: Lym-1 antibody-dependent cell-mediated cytotoxicity by an anti-Class II murine monoclonal antibody: Effects of recombinant IL-2 on human effector cell lysis of human B-cell tumors. *Cancer Res* May 15;50(10):2991-2996, 1990.
95. Foon KA, Rai KR and Gale RP: Chronic lymphocytic leukemia: New insights into biology and therapy. *Ann Intern Med* Oct 1;113(7):525-539, 1990.
96. Fanning J, Biddle WC, Goldrosen M, Crickard K, Crickard U, Piver S and Foon KA: Comparison of cisplatin and carboplatin cytotoxicity in human ovarian cancer cell lines using the MTT assay. *Gynecol Oncol* Nov;39(2):119-122, 1990.
97. Vaickus L, Biddle W, Cemerlic D and Foon KA: Gamma interferon augments Lym-1-dependent, granulocyte and mononuclear cell-mediated tumor lysis. *Blood* Jun 15;75(12):2408-2416, 1990.
98. Bhattacharya-Chatterjee M, Mukerjee S, Biddle W, Foon KA and Köhler H: Murine monoclonal anti-idiotypic antibody as a potential network antigen for human carcinoembryonic antigen. *J Immunol* Oct 15;145(8):2758-2765, 1990.
99. Chatterjee M, Barcos M, Han T, Liu X, Bernstein Z and Foon KA: Shared idiotype expression by chronic lymphocytic leukemia and B-cell lymphoma. *Blood* Nov 1;76(9):1825-1829, 1990.
100. Goldrosen MH, Biddle WC, Pancook J, Bakshi S, Vanderheyden JL, Morgan AC, Foon KA: Biodistribution, pharmacokinetic and imaging studies with <sup>186</sup>Re-labeled NR-LU-10 in LS174T colonic tumor-bearing mice. *Cancer Res* Dec 15;50(24):7973-7978, 1990.
101. VanderMolen LA, Steis RG, Duffey PL, Urba WJ, Foon KA, Smith SW II, Clark JW, Conlon K, Stevenson HC, Hartmann LC, Watson T, Jaffe ES and Longo DL: Low- vs high-dose interferon alfa-2a in relapsed low-grade non-Hodgkin's lymphoma. *J Natl Cancer Inst* 82:235-238, 1990.
102. Foon KA and Fanning J. Immunotherapy of gynecologic malignancies. *Semin Surg Oncol*. 6(6):364-368, 1990.

103. Bernstein ZP, Vaickus L, Friedman N, Goldrosen MH, Watanabe H, Rahman R, Arbuck SG, Sweeney J, Vesper D, Henderson ED, Zeffren J, Dennin RA, Levitt D and Foon KA: IL-2 LAK therapy of non-Hodgkin's lymphoma and Hodgkin's disease. *J Immunother* 10:141-146, 1991.
104. Rahman R, Bernstein Z, Vaickus L, Penetrante R, Arbuck S, Kopec I, Vesper D and Foon KA: Unusual gastrointestinal complications of interleukin-2 and lymphokine-activated killer cell therapy. *J Immunother Jun*;10(3):221-225 1991.
105. Bernstein ZP, Goldrosen MH, Vaickus L, Friedman N, Watanabe H, Rahman R, Park J, Arbuck SC
106. Vaickus L, Ball ED and Foon KA: Immune markers in hematologic malignancies. *Crit Rev Oncol/Hematol Dec*;11(4):267-297, 1991.
107. Foon KA, Walther PJ, Bernstein ZP, Vaickus L, Rahman R, Watanabe H, Sweeney J, Park J, Vesper D, Russell DF, Walker RA, Darrow TL, Linna TJ, Farmer DL, Lynch WJ Jr, Huben R and Goldrosen MH: Renal cell carcinoma treated with continuous infusion interleukin-2 with *ex vivo*-activated killer cells. *J Immunother Apr*;11(3):184-190, 1992.
108. Foon KA and Gale RP: Therapy of acute myelogenous leukemia. *Blood Rev Mar*;6(1):15-25, 1992.
109. Baer MR, Ozer H and Foon KA: Interferon-alpha therapy during pregnancy in chronic myelogenous leukemia and hairy cell leukemia. *Br J Haematol Jun*;81(2):167-169, 1992.
110. Foon KA and Gale RP: Is there a T-cell form of chronic lymphocytic leukemia: Fact or fiction? *Leukemia Sep*;6(9):867-868, 1992.
111. Foon KA and Piro LD. Lymphocytic leukemias: New insights into biology and therapy. *Leukemia Nov*;6(4):26-32, 1992.
112. Watanabe H, Narumi K, Stewart CC, Arbuck SG, Foon KA and Goldrosen MH: The effect of anti-CD3 on the induction of non-MHC restricted cytolytic activity. *Anticancer Res Nov-Dec*;12(6):1925-33, 1992.
113. Bernstein ZP, Fitzpatrick JE, O'Donnell A, Han T, Foon KA and Bhargava A: Clinical significance of monoclonal proteins in chronic lymphocytic leukemia. *Leukemia Dec*;6(12):1243-45, 1992.
114. Foon KA, Thiruvengadam R, Saven A, Bernstein ZP, Gale RP: Genetic relatedness of lymphoid malignancies: Transformation of chronic lymphocytic leukemia as a model. *Ann Int Med Jul* 1;119(1):63-73, 1993.
115. Chatterjee M, Foon KA, Mukerjee S, Petrelli N and Köhler H. Idiotypic matching: a network antigen idiotype is expressed in colon cancer patients' sera. *Vaccine Res.* 2(4):283-290, 1993.

116. Saven A, Foon KA, Piro LD: 2-Chlorodeoxyadenosine-induced complete remissions in Langerhans'-cell histiocytosis. *Ann Int Med* Sep 15;121(6):430-432, 1994.
117. Bhattacharya-Chatterjee M, Foon KA and Köhler H. Anti-idiotypic antibodies: Novel therapeutic approaches to the acquired immune deficiency syndrome and cancer. *Clin. Immunol. Immunother* Feb;38(2):75-82, 1994.
118. Foon KA. Chronic lymphoid leukemias: Recent advances in biology and therapy. *Stem Cells* Jan;13(1):1-21, 1995.
119. Foon KA, Chakraborty M, John WJ, Sherratt A, Köhler H, Bhattacharya-Chatterjee M. Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotypic antibody vaccine. *J Clin Invest* Jul;96(1):334-342, 1995.
120. Chakraborty M, Mukerjee S, Foon KA, Köhler H, Ceriani RL, Bhattacharya-Chatterjee M. Induction of anti-idiotypic antibodies. *J Clin Invest* 1;55(7):1525-1530, 1995.
121. Foon KA, Oseroff AR, Vaickus L, Greenberg SJ, Russell D, Bernstein Z, Pincus S, Köhler H, Seon B, Tahaoglu E, Beers T, Chakraborty M, Bhattacharya-Chatterjee M. Immune responses in patients with cutaneous T-cell lymphoma treated with an anti-idiotypic antibody mimicking a highly restricted T-cell antigen. *Clin Cancer Res* Nov 1(11):1285-1294, 1995.
122. Chakraborty, M, Foon KA, Köhler H and Bhattacharya-Chatterjee M. Preclinical evaluation in non-human primates of an anti-idiotypic antibody that mimicks the carcinoembryonic antigen. *J Immunotherapy* Aug;18(2):95-103, 1995.
123. Fleming DR, Henslee-Downey PJ, Harder EJ, Romond EH, Marciniak E, Munn RK, Messino MJ, Macdonald JS, Bishop MR, Rayens MK, Thompson JS, Foon KA. Allogeneic bone marrow transplantation with partially matched related donors for advanced acute lymphoblastic leukemia in children and adults. *Bone Marrow Transpl* Jun;17(6):917-22, 1996.
124. Sen G, Chakraborty M, Foon KA, Reisfeld RA, Bhattacharya-Chatterjee M. Induction of IgG antibodies by an anti-idiotypic antibody mimicking disialoganglioside GD2. *J Immunother* 21:75-83, 1997.
125. Jennings CD and Foon KA. Recent advances in flow cytometry: application to the diagnosis of hematologic malignancy. *Blood* Oct 15;90(8):2863-92, 1997.
126. Pervin S, Chakraborty M, Bhattacharya-Chatterjee M, Zeytin H, Foon KA, Chatterjee SK. Induction of anti-tumor immunity by an anti-idiotypic antibody mimicking carcinoembryonic antigen. *Cancer Res* Feb 15;57(4):728-734, 1997.
127. Foon KA, John WJ, Chakraborty M, Sherratt A, Garrison J, Flett M, Bhattacharya-Chatterjee M. Clinical and immune responses in advanced colorectal cancer patients treated with anti-

idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. Clin Cancer Res Aug;3(8):1267-1276, 1997.

128. Sen G, Chakraborty M, Foon KA, Reisfeld RA, Bhattacharya-Chatterjee M. Preclinical evaluation in nonhuman primates of an anti-idiotypic antibody that mimics the disialoganglioside GD2. Clin Cancer Res Nov;3(11):1969-1976, 1997.
129. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles T-M, Dallaire BK, Wey K, Royston I, Davis T, Levy R. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood Sep 15;90(6):2188-2195, 1997.
130. Davis BH, Foucar K, Szczarkowski, Ball E, Witzig T, Foon KA, Wells D, Dotylo P, Johnson R, Hanson C, Bessman D. U.S.-Canadian Consensus Recommendations on the Immunophenotypic Analysis of Hematologic Neoplasm by Flow Cytometry: Medical Indications. Cytometry (Communications in Clinical Cytometry) Oct 15;30(5):249-263, 1997.
131. Jennings CD and Foon KA. Flow cytometry: recent advances in diagnosis and monitoring of leukemia. Cancer Invest. 15(4):384-99, 1997.
132. Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, Foon KA, Markesbery WR, Young B. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA Nov 4;280(17):1485-9, 1998.
133. Chatterjee SK, Tripathi PK, Chakraborty M, Yannelli J, Wang H, Foon KA, Maier CC, Blalock EJ and Bhattacharya-Chatterjee M. Molecular mimicry of carcinoembryonic antigen by peptides derived from the structure of an anti-idiotypic antibody. Cancer Res. Mar 15;58(6):1217-1224, 1998.
134. Foon KA, Sen G, Hutchins L, Kashala OL, Baral R, Banerjee M, Chakraborty M, Garrison J, Reisfeld RA, Bhattacharya-Chatterjee M. Antibody response in melanoma patients immunized with an anti-idiotypic antibody mimicking disialoganglioside GD2. Clin Cancer Res. May;4(5):1117-1124, 1998.
135. Tripathi PK, Qin H, Deng S, Xu C, Bhattacharya-Chatterjee M, Foon, KA and Chatterjee S. Antigen mimicry by an anti-idiotypic antibody single chain variable fragment. Mol Immunol. Sept;35(13):853-63, 1998.
136. Foon KA, Bhattacharya-Chatterjee M. Idiotypic vaccines in the clinic. Nat Med. Aug;4(5):1117-24, 1998.
137. Sen G, Chakraborty M, Foon KA, Reisfeld RA and Bhattacharya-Chatterjee MB. Induction of IgG antibodies by an anti-idiotypic antibody mimicking disialoganglioside GD2.

- J Immunother. Jan;21(1):75-83, 1998.
138. Ryan JR, Rankin C, Devaney KO, Zalupski MM, Fletcher WS, Mills GM, Foon KA, and Antman K. Evaluation of tamoxifen in desmoid tumors: A Southwest Oncology Group Phase II Study. J Bone Joint Surg, (submitted)
  139. Foon KA, Yannelli J, Bhattacharya-Chatterjee M. Colorectal cancer as a model for immunotherapy. Clin Cancer Res. Feb;5(2):225-236, 1999.
  140. Tripathi, PK, Quin H-X, Bhattacharya-Chatterjee M, Ceriani RL, Foon KA, and Chatterjee SK. Construction and characterization of a chimeric fusion protein consisting of an anti-idiotypic antibody mimicking a breast cancer-associated antigen and the cytokine GM-CSF. Hybridoma Apr;18(2):193-202, 1999.
  141. Foon KA, John WJ, Chakraborty M, Das R, Teitelbaum A, Garrison J, Kashala O, Chatterjee SK, and Chatterjee M. Clinical and immune responses in resected colon cancer patients treated with anti-idiotypic monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J Clin Oncol. Sept;17(9):2889-2895, 1999.
  142. Foon KA, Lutzky J, Rathindra BN, Yannelli JR, Hutchins L, Teitelbaum A, Kashala OL, Das R, Garrison J, Reisfeld RA, and Chatterjee M. Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotypic antibody mimicking disialoganglioside GD2. J Clin Oncol. Jan;18(2):376-384, 2000.
  143. Reece D, Foon KA, Bhattacharya-Chatterjee M, Hale GA, Howard DS, Munn RK, Nath R, Plummer BA, Teitelbaum A and Phillips GL. Use of the anti-idiotypic antibody vaccine Tri-Ab after autologous stem cell transplantation in patients with metastatic breast cancer. Bone Marrow Transplant. Oct;26(7):729-35, 2000.
  144. Bhattacharya-Chatterjee M, Chatterjee SK and Foon KA. Anti-idiotypic vaccine against cancer. Immunol Lett. Sept 15; 74(1):51-58, 2000.
  145. Foon KA. Monoclonal antibody therapies for lymphomas. The Cancer Journal Sept. Oct;6(5):273-278, 2000.
  146. Zeytin HE, Tripathi PK, Bhattacharya-Chatterjee M, Foon KA and Chatterjee SK. Construction and characterization of DNA vaccines encoding the single chain variable fragment of the anti-idiotypic antibody 1A7 mimicking the tumor-associated antigen disialoganglioside GD2. Cancer Gene Therapy, Nov;7(11):1426-1436, 2000.
  147. Safa MM and Foon KA. Adjuvant immunotherapy for melanoma and colorectal cancers. *Seminars in Oncology* Feb;28(1):68-92, 2001.



148. Rohatgi N, Bhatnagar A, Lowy A, Bhattacharya-Chatterjee M, Bard V, Baral R, Saha A, Das R, Shukla R, John WJ and Foon KA. Treatment of resected colorectal cancer patients with the CeaVac anti-idiotypic monoclonal antibody vaccine that mimics the carcinoembryonic antigen. (Submitted to J Clin Oncol.)
149. Baral R, Sherratt A, Das R, Foon KA and Bhattacharya-Chatterjee M. Murine monoclonal anti-idiotypic antibody as a surrogate antigen for human HER2/Neu. (In Press International J Cancer).
150. Foon KA and Bhattacharya-Chatterjee M. Are solid tumor anti-idiotypic vaccines ready for prime time? (Editorial Clin Cancer Res. ).
151. Qin H-X, Valentino J, Manna S, Tripathi PK, Bhattacharya-Chatterjee M, Foon KA, O'Malley BW and Chatterjee, SK. Therapy of head and neck cancer by recombinant vaccinia virus expressing IL-2 in a murine model with evidence of immune suppression (Submitted to Int. J. Cancer).
152. Safa M, Lutzky J, Bhattacharya-Chatterjee M, Baral RN, Das R, Saha A, Sussman J, Bard V, McAfee S, Shukla R, Sethuraman G, Reisfeld RA, Hutchins L, Bhatnagar A, Foon KA. TriGem anti-idiotypic monoclonal antibody vaccine treatment for stage III melanoma: results of a multicenter phase III trial. (Submitted J Clin Oncol.)

B. *Non Peer-Reviewed Manuscripts and Book Chapters:*

1. Cline MJ, Fitch JH, Foon KA and Billing RJ: Antigenic characteristics of normal and malignant hematopoietic cells. Potential use of antigenic differences in cell separation and marrow transplantation. *Exp Hematol* 7(Suppl 5):246-251, 1979.
2. Foon KA, Fitch JH, Billing RJ, Belzer MB, Wells JR, Golde DW, Gale RP and Cline MJ: Hematopoietic stem cell antigens. In: *Biology of Bone Marrow Transplantation*. ICN-UCLA Symposia on Molecular and Cellular Biology, Vol. XVII, RP Gale and CF Fox (eds). Academic Press, New York, 1980, pp 477-490.
3. Billings, RJ, Wells JR, Gale RP, Foon KA, Linker-Israeli M, Deng C, Terasaki PI and Cline MJ: *In vitro* treatment of bone marrow with heteroantisera prior to transplantation. In: *Biology of Bone Marrow Transplantation*, ICN-UCLA Symposia on Molecular and Cellular Biology, Vol. XVII, RP Gale and CF Fox (eds). Academic Press, New York, 1980, pp 167-174.
4. Foon KA and Fitch JH: Antigenic structure of hematopoietic stem cells. In: *Fetal Liver Transplantation: Current Concepts and Future Directions*, GL Lucareli, TM Flidner and RP Gale (eds). Excerpta Medica, Amsterdam, 1980, pp 167-174.

5. Foon KA and Billing RJ: Immunologic classification of the lymphoid leukemias: A probe for normal lymphoid differentiation. *UCLA Cancer Ctr Bull* 7:5-8, 1981.
6. Ciciarelli JC, Foon KA and Terasaki PI: Leukocyte antigens. *In: Methods in Hematology*, MJ Cline (ed). Churchill-Livingston, 1981, pp 84-108.
7. Foon KA and Costea N: Acquired hemolytic anemias. *In: Internal Medicine*, JH Stein (ed). Little, Brown and Co., Boston, 1982, pp 1564-1571.
8. Gale RP and Foon KA: Chronic myeloproliferative disorders. *In: Internal Medicine*, JH Stein (ed). Little, Brown and Co., Boston, 1982, pp 1632-1638.
9. Gale RP, Foon KA, Yale C and Zighelboim J: Immunotherapy of acute myelogenous leukemia using corynebacterium parvum and leukemia cells. *In: Immunotherapy of Human Cancer*, WD Terry and SS Rosenberg (eds). Elsevier North Holland, Inc., New York, 1982, pp 39-43.
10. Gale RP, Levine A, Golde DW, Bloomfield C and Foon KA: Chronic leukemias. *In: Hematology*, JR McArthur and RS Hillman (eds). Charles B. Slack, Inc., Thorofare, New Jersey, 1982, pp. 8-14.
11. Foon KA and Gale RP: Therapy of acute myelogenous leukemia. *In: Cancer Chemotherapy 1*, FM Muggia (ed). Martinus Nijhoff Publishers, 1983, pp 303-331.
12. Foon KA and Gale RP: Treatment of elderly patients with acute myelogenous leukemia. *Geriatr Med Today* 2:48-61, 1983.
13. Gale RP, Levine A, Champlin R, Bloomfield C and Foon KA: Chronic leukemias. *In: Hematology*, JR McArthur and RS Hillman (eds). Charles B. Slack, Inc., Thorofare, New Jersey, 1983, pp 16-24.
14. Oldham RK, Sherwin SA, Maluish A, Long CW, Watson T and Foon KA: A phase I trial of immune interferon: A preliminary report. *In: Thymic Hormones and Lymphokines*, Goldstein AL (ed). Plenum Press, 1983.
15. Foon KA, Schroff RW, Mayer D, Sherwin SA, Oldham RK, Bunn PA and Hsu S-M: Monoclonal antibody therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma: Preliminary observations. *In: Monoclonal Antibodies and Cancer*, BD Boss, RE Langman, IS Trowbridge and R Dulbecco (eds). Academic Press, New York, 1983, pp 39-52.
16. Foon KA, Abrams PG, Rossio JL, Knost JA and Oldham RK: Human hybridomas: Comparison of human cell lines for production of human hybridomas and development of human hybridomas producing antigen-specific IgG using *in vitro* immunized peripheral blood cells as fusing partners. *In: Monoclonal Antibodies and Cancer*, BD Boss, RE

- Langman, IS Trowbridge and R Dulbecco (eds). Academic Press, New York, 1983, pp 143-155.
17. Foon KA, Sherwin SA, Bunn PA, Longo D and Oldham RK: Recombinant leukocyte A interferon in the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and mycosis fungoides. In: Interferon: Research, Clinical Application and Regulatory Consideration, KC Zoon, PD Noguchi and TY Liu (eds). Elsevier Science Publishing Company, Inc., New York, 1984, pp 219-227.
  18. Foon KA and Gale RP: Acute myelogenous leukemia: Recent advances in diagnosis and therapy. In: Contemporary Hematology-Oncology, Vol. 3. AS Gordon, J LoBue and R Silber (eds). Plenum Publishing Corp., New York, 1984, pp 171-214.
  19. Foon KA and Gale RP: Acute myelogenous leukemia: Current status of therapy in adults. In: Recent Results in Cancer Research, Vol. 93, E Thiel and S Thierfelder (eds). Springer-Verlag, Berlin, Heidelberg, New York, 1984, pp 216-239.
  20. Oldham RK, Thurman GB, Talmadge JE, Stevenson HC and Foon KA: Lymphokines, monoclonal antibody, and other biological response modifiers in the treatment of cancer. *Cancer* 54:2795-2806, 1984.
  21. Oldham RK, Foon KA, Sherwin SA and Rudnick S: New biological approaches in the treatment of cancer (booklet). Am Soc Clin Oncol Educational Symposium and Educational Workshop, Bostrom Management Corp., 1984, pp 33-46.
  22. Morgan AC, Pavanadasivan G, Hwang KM, Woodhouse CS, Schroff RW, Foon KA and Oldham RK: Preclinical and clinical evaluation of a monoclonal antibody to a human melanoma-associated antigen. In: Protides of the Biological Fluids, H Peeters (ed). Pergamon Press, Oxford, New York, 1984, pp 773-777.
  23. Foon KA and Schroff RW: Monoclonal antibodies in cancer therapy: The NCI-BRMP experience. *Clin Immunol Today* 11:1-3, 1984.
  24. Levine AM, Foon KA and Portlock C: Non-Hodgkin's lymphoma. In: Hematology, DI Feinstein and JR McArthur (eds). Charles B. Slack, Inc., Thorofare, New Jersey, 1984, pp 19-23.
  25. Zighelboim J, Foon KA, Gale RP and Haskell CM: Acute myelogenous leukemia. In: Cancer Treatment, CM Haskell (ed). WB Saunders Co., Philadelphia, 1985, pp 594-705.
  26. Foon KA and Bottino GC: Immunology of acute leukemia. In: Neoplastic Diseases of the Blood, PH Wiernik, G Cannellos, R Kyle and C Schiffer (eds). Churchill Livingstone, New York, 1985, pp 219-247.

27. Foon KA: Treatment of leukemia and lymphoma with biological response modifiers. In: *Biology and Therapy of Acute Leukemia*, L Baker, F Valeriote and V Ratanatharathorn (eds). Martinus Nijhoff, Boston, 1985, pp 213-229.
28. Foon KA: Biological approaches to the therapy of lymphoproliferative diseases. In: *Lymphoproliferative Diseases: Pathogenesis, Diagnosis and Therapy*, PK Pattengale, RJ Lukes and CR Taylor (eds). Martinus Nijhoff Publishers, Boston, 1985, pp 152-170.
29. Bunn PA, Foon KA, Ihde DC, Longo D, Schroff RW, Minna JD, Carrasquillo J, Keenan A, Larson S and Glatstein E: Treatment of cutaneous T-cell lymphomas with biologic response modifiers: Recombinant leukocyte A interferon and T101 monoclonal antibody. In: *Malignant Lymphomas and Hodgkin's Disease: Experimental and Therapeutic Advances*, F Cavalli, G Bonadonna and M Rozenzweig (eds). Martinus Nijhoff Publishers, Boston, 1985, pp 579-590.
30. Gale RP and Foon KA: Therapy of acute myelogenous leukemia. In: *Leukemia: Recent Advances in Biology and Treatment*, RP Gale and DW Golde (eds). Alan R. Liss, Inc., New York, 1985, pp 609-649.
31. Foon KA and Gale RP: Recent advances in biology and treatment of chronic lymphocytic leukemia. In: *Leukemia: Recent Advances in Biology and Treatment*, RP Gale and DW Golde (eds). Alan R. Liss, New York, 1985, pp 675-714.
32. Bunn PA Jr and Foon KA: Therapeutic options in advanced cutaneous T-cell lymphomas: A role for interferon alpha-2a (Roferon  $\alpha$ -2A), *Semin Oncol* 12(Suppl 5):25-29, 1985.
33. Levine AM, Foon KA and Horning S: Non-Hodgkin's lymphoma In: *Hematology*, DI Feinstein and JR McArthur (eds). Charles B. Slack, Inc., Thorofare, New Jersey, 1985, pp 24-28.
34. Foon KA, Schroff RW and Gale RP: Surface markers on leukemia and lymphoma cells: Recent advances. *Leucemie e Linfomi, Diagnosi e Terapia*, C.E.A., Casa Editrice Ambrosiana - Milano, 1985, pp 205-229.
35. Abrams PG, Morgan AC, Schroff CJ and Foon KA: Monoclonal antibody studies in melanoma. In: *Monoclonal Antibodies and Cancer Therapy*, R Reisfeld and K Sell (eds). UCLA Symposium on Molecular and Cellular Biology. Alan R. Liss, New York, 1985, pp 233-236.
36. Morgan AC and Foon KA: Monoclonal antibody therapy of cancer: Pre-clinical models and investigations in man. In: *Basic and Clinical Tumor Immunology*, RB Herberman (ed). Martinus Nijhoff Publishers, Boston, 1986, pp 177-200.
37. Foon KA, Schroff RW and Bunn PA: Monoclonal antibody therapy for patients with leukemia and lymphoma. In: *Monoclonal Antibody Therapy of Human Cancer*, KA Foon and AC Morgan (eds). Martinus Nijhoff Publishers, Boston, 1986, pp 85-101.

38. Foon KA and Gale RP: Principles of leukemia treatment. In: Leukemia Therapy, RP Gale (ed). Blackwell Scientific Publications, Inc., Boston, 1986, pp 1-23.
39. Gale RP and Foon KA: Therapy of acute myelogenous leukemia. In: Leukemia Therapy, RP Gale (ed). Blackwell Scientific Publications, Inc., Boston, 1986, pp 99-145.
40. Foon KA and Gale RP: Therapy of chronic lymphocytic leukemia. In: Leukemia Therapy, RP Gale (ed). Blackwell Scientific Publications, Inc., Boston, 1986, pp 165-180.
41. Abrams PG, Morgan AC, Schroff RW, Woodhouse CS, Carrasquillo J, Stevenson HC, Fer MF, Oldham RK and Foon KA: Localization and biodistribution studies of a monoclonal antibody in patients with melanoma. In: Monoclonal Antibodies and Cancer Therapy, R Reisfeld and K Sell (eds). Alan R. Liss, New York, 1986, pp 233-236.
42. Foon KA and Morgan AC: Monoclonal antibody therapy of cancer: Animal models and human trials. In: Monoclonal Antibodies in Cancer: Advances in Diagnosis and Treatment, JA Roth (ed). Futura Publishing Co., Mount Kisco, NY, 1986, pp 141-171.
43. Stevenson HC, Foon KA and Sugarbaker PH: *Ex vivo* activated monocytes and adoptive immunotherapy trials in colon cancer patients. In: Transfusion Medicine: Recent Technological Advances. Alan R. Liss, New York, 1986, pp 75-82.
44. Foon KA, Schroff RW and Bunn PA: Clinical applications of monoclonal antibodies in patients w
45. Foon KA: Interferon therapy of the lymphoproliferative disorders. *Semin Hematol* 23(Suppl 1):10-13, 1986.
46. Foon KA: Biological therapy of cancer. *Breast Cancer Res Treat* 7:5-14, 1986.
47. Gale RP and Foon KA: Acute myeloid leukemia: Recent advances in therapy. *Clin Haematol* 15:781-810, 1986.
48. Foon KA, Gale RP and Todd RF III: Recent advances in the immunologic classification of leukemias. *Semin Hematol* 23:257-283, 1986.
49. Foon KA, Order SE and Rosenberg SA: *Role of Biologics in Cancer Treatment*, Am Soc Clin Oncol, Educational Booklet, Bostrom Corp., Chicago, 1986, pp 19-27.
50. Foon KA and Bunn PA Jr: Alpha interferon treatment of cutaneous T-cell lymphoma and chronic lymphocytic leukemia. *Semin Oncol* 13(Suppl 5):35-39, 1986.
51. Foon KA, Roth MS and Bunn PA Jr: Alpha interferon treatment of low-grade B-cell non-Hodgkin's lymphoma, cutaneous T-cell lymphoma and chronic lymphocytic leukemia. *Semin Oncol* 13(Suppl 2):35-42, 1986.

52. Golomb HM, Foon KA and Parkinson DA: Biologic response modifiers. In: Hematology. 1986, pp 64-70.
53. Foon KA and Gale RP: Principles of leukemia treatment. In: Leukemia, JA Whittaker and IW Delamore (eds). Blackwell Scientific Publications, Ltd., Osney Mead, Oxford, 1987, pp 270-285.
54. Foon KA and Gale RP: Immunologic classification of lymphoma and lymphoid leukemias. *Blood Rev* 1:77-88, 1987.
55. Foon KA and Gale RP: Therapy of chronic lymphocytic leukemia. In: Chronic Lymphocytic Leukemia: Recent Progress and Future Directions, RP Gale and K Rai (eds). Alan R. Liss, Inc., New York, 1987, pp 307-316.
56. Foon KA, Roth MS and Gale RP: Biological therapy of chronic lymphocytic leukemia. In: Chronic Lymphocytic Leukemia: Recent Progress and Future Directions, RP Gale and K Rai (eds). Alan R. Liss, Inc., New York, 1987, pp 353-366.
57. Steis RG, Foon KA and Longo DL: Current and future uses of recombinant alpha-interferon in the treatment of low-grade non-Hodgkin's lymphoma. *Cancer* 59(Suppl):658-663, 1987.
58. Foon KA and Gale RP: Staging and therapy of chronic lymphocytic leukemia. *Semin Hematol* 24:264-274, 1987.
59. Gale RP and Foon KA: Biology of chronic lymphocytic leukemia. *Semin Hematol* 24:209-229, 1987.
60. Foon KA, Roth MS and Bunn PA Jr: Interferon therapy of non-Hodgkin's lymphoma. *Cancer* 59(Suppl):601-604, 1987.
61. Roth MS and Foon KA: Current status of interferon therapy in oncology. *Prog Hematol* XV, 19-38, 1987.
62. Sherwin SA, Foon KA and Oldham RK: Animal tumor models for biological response modifier therapy: An approach to the development of monoclonal antibody therapy in humans. In: Fundamentals of Cancer Chemotherapy, K Hellman and S Carter (eds). McGraw-Hill Book Co., 1987, pp 202-211.
63. Golomb HM, Foon KA and Parkinson DA: Biologic response modifiers. In: Hematology. 1987, pp 69-76.
64. Gale RP and Foon KA: Therapy of acute myelogenous leukemia. *Semin Hematol* 24:40-54, 1987.
65. Bunn PA, Ihde PC and Foon KA: Recombinant interferon alpha-2a, an active agent in advanced cutaneous T-cell lymphomas. *Int J Cancer (Suppl 1)*:9-13, 1987.

66. Roth MS and Foon KA: Biotherapy with interferon in hematologic malignancies. *Oncol Nurs* 14(Suppl 6):16-22, 1987.
67. Roth MS and Foon KA: Interferon: Biology and therapy in human cancer. *In: Immunology in New Drug Development*, J Sinkule (ed). Pergamon Books, Inc., Elmsford, NY, 1987.
68. Foon KA: Biological approaches to cancer therapy. *In: Modern Trends in Human Leukemia VII*, R Neth, RC Gallo, MF Greaves and H Kabisch (eds). Springer-Verlag, Berlin, 1987, pp 103-109.
69. Foon KA: Advances in cancer: Monoclonal antibody therapy of hematologic malignancies. *New Jersey Medicine* 84:269-274, 1987.
70. Foon KA and Gale RP: Interferon in chronic lymphocytic leukemias and herpes zoster infections in leukemia patients. *In: Clinical Aspects of Interferon*, M Revel (ed). Martinus Nijhoff Publishing, Boston, 1988, pp 141-148.
71. Roth MS and Foon KA: Clinical aspects of interferon therapy in human cancer. *In: Cytotoxic Lymphokines and Cancer: Biological and Chemical Aspects*, JH Ranson and J Ortaldo (eds). Humana Press, 1988, pp 247-271.
72. Foon KA, Gale RP and Todd R III: Immunological classification of lymphoma and lymphoid leukemias. *In: Lymphomas/Leukemias III: Immunologic Approaches to the Classification and Management of Lymphomas and Leukemias*, JM Bennett and KA Foon (eds). Martinus Nijhoff Publishing, Boston, 1988, pp 1-30.
73. Roth MS, Bunn PA and Foon KA: Interferon therapy for lymphoproliferative disorders. *In: Lymphomas/Leukemias III: Immunologic Approaches to the Classification and Management of Lymphomas and Leukemias*, JM Bennett and KA Foon (eds). Martinus Nijhoff Publishing, Boston, 1988, pp 231-252.
74. Kaminski MS and Foon KA: Monoclonal antibody therapy of lymphomas and leukemias. *In: Lymphomas/Leukemias III: Immunologic Approaches to the Classification and Management of Lymphomas and Leukemias*, JM Bennett and KA Foon (eds). Martinus Nijhoff Publishing, Boston, 1988, pp 253-263.
75. Foon KA, Gale RP and Todd RF III: Immunologic classification of leukemia. *In: Leukemia*, AM Mauer (ed). Johns Hopkins University Press, Baltimore, 1988.
76. Foon KA: Advances in immunotherapy of cancer: Monoclonal antibodies and interferon. *Semin Nurs Oncol* 4:112-119, 1988.
77. Mitchell MS and Foon KA: Lymphokines. *Immunol Allergy Clin North Am* 8:121-135, 1988.

78. Abrams DI, Foon KA and Gold JW: Lymphadenopathy: A diagnostic plan. *Patient Care*, 4:95-112, 1988.
79. Foon KA and Casciato DA: Chronic leukemias. In: *Manual of Clinical Oncology*, DA Casciato and BB Lowitz (eds). Little, Brown and Co., Boston, 2nd Edition, 1988, pp 360-375.
80. Foon KA and Casciato DA: Chronic leukemias. In: *Manual of Clinical Oncology*, DA Casciato and BB Lowitz (eds). Little, Brown and Co., Boston, 2nd Edition, 1988, pp 386-400.
81. Foon KA: Biotherapy of cancer with interleukin-2, colony stimulating factors, and monoclonal antibodies. *Nurs Forum* 15:(6):13-22, 1988.
82. Foon KA and Gale RP: Chronic lymphocytic leukemia and related diseases. In: *Recent Advances in Haematology 5*, AV Hoffbrand (ed). Churchill-Livingston, London, 1988, pp 179-209.
83. Gale RP and Foon KA: Biology of chronic lymphocytic leukemia. In: *Chronic Lymphocytic Leukemia*, A Polliack and D Catovsky (ed). Harwood Acad, Switzerland, 1988, pp 263-287.
84. Foon KA and Gale RP: Staging and therapy of chronic lymphocytic leukemia. In: *Chronic Lymphocytic Leukemia*, A Polliack and D Catovsky (eds). Harwood Acad, Switzerland, 1988, pp 139-158.
85. Foon K and Gale RP: Clinical transformation of chronic lymphocytic leukemia. *Nouv Rev Fr Hematol* 30:385-388, 1988.
86. Foon KA and Gale RP: Chemotherapy of acute myelogenous leukemia. In: *Bone Marrow Transplantation*. Alan R. Liss, New York, 1989, pp 75-94.
87. Foon KA: Laboratory and clinical applications of monoclonal antibodies for leukemias and non-Hodgkin's lymphomas. *Curr Probl Cancer* 13:57-128, 1989.
88. Gale RP and Foon KA: The chronic leukemias. In: *Conn's Current Therapy*, RE Rakel (ed). WB Saunders Co., 1989, pp 376-384.
89. Vaickus L and Foon KA: Role of monoclonal antibodies in oncology. *Hospital Formulary. The P & T Committee Journal* 24:704-710, 1989.
90. Foon KA, Champlin RE and Gale RP: Acute myelogenous leukemia and the myelodysplastic syndromes. In: *Cancer Treatment*, CM Haskell (ed). WB Saunders Co., Philadelphia, 3rd Edition, pp 589-606, 1990.



91. Vaickus L and Foon KA: Clinical application of monoclonal antibodies in oncology. Hospital Formulary. The P & T Committee Journal 25(1):50-56, 1990.
92. Foon KA and Gale RP: The chronic leukemias. In: Conn's Current Therapy, RE Rakel (ed). WB Saunders Co., pp 363-373, 1990.
93. Foon KA, Champlin RE and Gale RE: Therapy of acute lymphoblastic leukemia. UCLA Symposium. In: Acute Lymphoblastic Leukemia, Vol. 108., pp 157-196, 1990.
94. Vaickus L and Foon KA: Commentary: Monoclonal antibody therapy of lymphoproliferative disorders. Oncology 4(3):90, 1990.
95. Foon KA and Gale RP: Alternate first-line treatment for acute myelogenous leukemia. In: Acute M
96. Foon KA and Fanning J: Immunotherapy of gynecologic malignancies. Semin Surg Oncol 6:364-368, 1990.
97. Foon KA and Gale RP: Chronic lymphoid leukemias. In: Blood: Principles and Practice of Hematology, RI Handin, SE Lux and TP Stossel (Eds). JB Lippincot and Co., Philadelphia, 1990.
98. Vaickus L and Foon KA: Biological therapies of lymphomas. In: Malignant Lymphoma: Biology, Diagnosis and Treatment, CW Erber, S Flecknoe-Brown and M Garson (eds)., pp 177-198, 1991.
99. Vaickus L and Foon KA: Immunology of acute leukemia. In: Neoplastic Diseases of the Blood, PH Wiernik, GP Canellos, RA Kyle and CA Schiffer (eds), 2nd Edition. Churchill-Livingstone, New York, pp 183-214, 1991.
100. Vaickus L and Foon KA: Overview of monoclonal antibodies in the diagnosis and therapy of cancer. Cancer Invest 9(2):195-210, 1991.
101. Bhattacharya-Chatterjee M, Foon KA and Köhler H: Anti-idiotypic monoclonal antibodies as vaccines for human cancer. Int Rev Immunol 7(4):289-302, 1991.
102. Foon KA, Chronic Lymphocytic Leukemia. Cortlandh Forum, July 1992, 160-163.
103. Bhattacharya-Chatterjee M, Foon KA and Köhler H: Anti-idiotypic approaches to cancer therapy. Contemp Oncology 2:27-36, 1992.
104. Köhler, H, Müller S, Chatterjee M and Foon KA. Therapeutic anti-clonotypic antibodies. Proceed. 8th Internat'l. Congress Immunol., Springer Verlag, p. 619-626, 1992.
105. Stickney D, Foon KA: Biological Response Modifiers: Therapeutic Approaches to Lymphoproliferative Diseases. Current Opinion in Oncology Oct;4(5):847-855, 1992.

106. Biddle WC and Foon KA: Monoclonal antibodies in therapy, alone or conjugated with drugs. Review chapter for inclusion in: *The Biomodulation of Cancer*, Malcolm M (ed). McGraw-Hill, Inc., pp 207-251, 1992.
107. Foon KA, Robbins BA, Ellison DJ and Vaickus L: Immune surface markers in lymphoproliferative disorders. *Adv Leuk Lymphoma* 3:3-11, 1992.
108. Vaickus L, Ball ED and Foon KA: Immunologic classifications of leukemias. In: *Clinical Cancer Markers: Diagnosis, Prognosis and Monitoring*, S Sell (ed). Humana Press, 1992.
109. Vaickus L and Foon KA. In: *Leukemia. Encyclopedia of Science and Technology*, 7th Edition. McGraw-Hill Book, New York, 1992.
110. Schiller GJ, Foon KA and Gale RP: Principles of leukemia treatment. In: *Leukemia*, Whittaker JA (ed), 2nd Edition. Blackwell Scientific Publications, Ltd., pp 329-354, 1992.
111. Bloomfield CD, Foon KA and Levine EG: Leukemias. In: *Medical Oncology*, Calabrese T and Schein PS (eds). Pergamon Press, New York, pp. 459-502, 1993.
112. Foon KA, Rai KR and Gale RP: Chronic lymphocytic leukemia. In: *Hematology Clinical and Laboratory Practice*, Bick RL (ed). Mosby, St. Louis, pp. 803-815, 1993.
113. Foon KA and Gale RP: Cutaneous T-cell lymphoma. In: *Hematology Clinical and Laboratory Practice*, Bick RL (ed). Mosby, St. Louis, pp. 841-844, 1993.
114. Foon KA. Clinical simulations in the management of Chronic Lymphocytic Leukemia *Medical Age Publishing*, Norwalk, Connecticut, p. 1-15, 1993.
115. Foon KA and Chatterjee M: Anti-idiotypic antibodies: novel therapeutic approaches to cancer therapy. In: *Tumor Immunology: Basic Mechanism and Prospects for Therapy*. Goldfarb/Whiteside (Eds.), Marcel Dekker, Inc., New York, N.Y., Chapter 23, p. 281-292, 1993.
116. Chatterjee M, Mrozek E, Vaickus L, Oseroff A, Stoll H, Russel D, Köhler H and Foon KA. Anti-idiotypic (Ab2) vaccine therapy for cutaneous T cell lymphoma (CTCL). *Ann NY Acad Sci* Aug 12;690:376-378, 1993.
117. Foon KA. The Cytokine Network. *Oncology Supp*, 7(12), pp. 11-15, 1993.
118. Foon KA and Bhattacharya-Chatterjee M. *Anti-Idiotypic Antibodies: Novel Therapeutic Approach to Cancer Therapy*. Marcel Dekker, Inc., 1994.
119. Bhattacharya-Chatterjee M, Mrozek E, Mukerjee S, Ceriani RL, Köhler H, Foon KA. Anti-idiotypic antibodies as potential therapeutic agents for human breast cancer. *Adv Exp Med Biol* 353:139-48, 1994.

120. Foon KA, Bhattacharya-Chatterjee M. Anti-idiotypic antibodies: novel therapeutic approach to cancer therapy. *Immunol Ser* 61:281-92, 1994.
121. Bhattacharya-Chatterjee M, Mrozek E, Mukerjee S, Ceriani RL, Kohler H and Foon KA. Anti-Idiotypic Antibodies as Potential Therapeutic Agents for Human Breast Cancer. *In: Proceed 5th Inter. Conf. on Breast Cancer Therapy & Immunology*, RL Ceriani (Ed.), Plenum Press, NY., 139-148, 1994.
122. Foon KA and Fisher RI. Lymphomas. *In: Williams Hematology*, Fifth Edition (Eds. EP Beutler, MA Lichtman, BS Collier and TJ Kipps), McGraw-Hill, Inc., 1995.
123. Köhler H, Bhattacharya-Chatterjee M, Muller S and Foon KA. Idiotypic Manipulation in Disease Management. *In: Immunobiology of Proteins and Peptides*, Eighth Edition (Eds. M. Zouhair Atassi and G. Bixler, Jr.), Arizona Plenum Press, Proceedings of the Annual Symposium on Immunobiology of Proteins and Peptides, New York. *Adv Exp Med Biol* 383:117-122, 1995.
124. John WJ and Foon KA. *Clinical Applications of Interferon in Other Tumors*. J.B Lippincott Co, Philadelphia, 1995.
125. Chakraborty M, Foon KA, Köhler H, Bhattacharya-Chatterjee M. Preclinical evaluation in nonhuman primates of an anti-idiotypic antibody that mimicks the carcinoembryonic antigen. *J Immunother Emphasis Tumor Immunol* 18(2):95-103, Aug 1995.
126. 129. Bhattacharya-Chatterjee M, Kohler H and Foon KA. Idiotypes in cancer. *In: Idiotypes in Medicine - Infections, Autoimmunity and Cancer*. Shoenfeld/Ferrone/Kennedy (Eds), Elsevier Science, Amsterdam, The Netherlands, B.V. p441-453, 1997.
127. Bhattacharya-Chatterjee M, Foon KA. Tumor markers and immunotherapy of cancer. *In: Clinical Immunology*. PC Sen Gupta (Ed), Oxford University Press. (In press), 1998.
128. Foon KA. Interferon therapy of hematologic malignancies. *In: Cancer Treat Res*. 94:1-21, 1998.
129. John WJ and Foon KA. Interferon use in solid tumors. *In: Cancer Treat Res*. 94:23-33, 1998.
130. Foon KA. Chronic lymphoid leukemias. *In: Manual of Clinical Hematology*. Little Brown & Co., Boston, M.A. pp. 461-478, 2000.
131. Foon KA and Casciato DA. Acute leukemia. *In: Manual of Clinical Oncology* (Ed. Casciato DA), Little Brown & Co., Boston, M.A. pp. 496-513, 2000.
132. Bhattacharya-Chatterjee M and Foon KA. Anti-idiotypic antibody vaccine therapies of cancer. *In: Cancer Treat Res*. 94:51-68, 1998.

133. Foon KA and Casciato DA. Chronic leukemias. In: Manual of Clinical Oncology (Ed. Casciato DA), Little Brown & Co., Boston, M.A. Fourth Ed. pp461-478, 2000.
134. Foon KA, Fisher RI. Lymphomas. In: Williams Hematology, Sixth Edition (Eds. EP Beutler, MA Lichtman, BS Collier and TJ Kipps), McGraw-Hill, Inc., 1999.
135. Bhattacharya-Chatterjee M, Chakraborty M, Chatterjee SK, John WJ and Foon KA. Vaccine therapy of colorectal cancer patients with an Anti-Id Mab that mimics carcinoembryonic antigen. *Proc. 10<sup>th</sup> International Congress of Immunology*, New Delhi, India, Monduzzi, M. Editor, p. 1503-1507, 1999.
136. Chatterjee SK, Qin H-X, Tripathi PK, Deng S, Bhattacharya-Chatterjee M and Foon KA. Anti-carcinoembryonic antigen (CEA) immunity induced by a single chain FV format of an anti-idiotypic antibody mimicking CEA. *Proc. 10<sup>th</sup> Intl. Congress of Immunology*, New Delhi, India, Monduzzi M. Editor, p. 1223-1227, 1999.
137. Arnold SM, Patchell R, Lowy AM and Foon KA. Paraneoplastic syndromes. In: Principles and Practices of Oncology, Fifth Edition (Eds. VT DeVita, S Hellman, and SA Rosenberg), J.B. Lippincott Co., 46:2397-2422, 1997.
138. Foon KA and LaRocca RV. Sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine and prednisone: effective therapy for follicle center lymphomas, follicular grades I and II. In: Purine Analogues, June Vol. 2, No.1, 1999.
139. Foon KA and Bhattacharya-Chatterjee M. GI cancer management: biological therapy. *Principles and Practice of Gastrointestinal Oncology*, Levin, B (Ed) Lippincott Williams and Wilkins (In Press).
140. Foon KA. Monoclonal antibodies in the treatment of lymphomas for the year 2000. In: Cancer: Principles and Practice of Oncology, May Vol.14, No. 4, 2000.
141. Foon KA. Monoclonal antibodies: basic principles, basic concepts and antigens recognized. *Principles and Practice of Oncology*, 3<sup>rd</sup> Edition, Section 14.1, pp371-381, 2000.
142. Foon KA. Basic concepts and antigens recognized, In: Principles and Practice of the Biologic Therapy of Cancer, 3<sup>rd</sup> Edition, Monoclonal Antibodies: Basic Principles, Section 14.1, pp371-381, 2000 .
143. Bhattacharya-Chatterjee M, Nath Baral R, Chatterjee SK, Das R, Zeytin H, Chakraborty M, and Foon KA. Counterpoint. Cancer vaccines: single-epitope anti-idiotypic vaccine versus multiple-epitope antigen vaccine. *Cancer Immunol Immunother.* Jun;49(3):133-141, 2000.
144. Bhattacharya-Chatterjee M, Chatterjee SK and Foon KA. The Anti-idiotypic vaccines for

immunotherapy. *Current Opinions in Molecular Therapeutics*, Feb;3(1): 63-39, 2001.

145. Foon KA. Immunotherapy for colorectal cancer. *Current Oncology Reports* Mar;3(2):116-126, 2001.
146. Foon KA. Cancer Vaccines. *Schwab: Encyclopedic Reference of Cancer*, Deutsches Krebsforschungszentrum, Heidelberg, Germany. ( in press).
147. Foon KA and Bhattacharya-Chatterjee M. Are solid tumor anti-idiotypic vaccines ready for prime time? *Clin Cancer Res* (in press).
148. Foon, KA. Immune Therapy Strategies for Colorectal Cancer. *Colorectal Cancer: Index and Reviews*. (in press).

## 2. Books

1. *Monoclonal Antibody Therapy of Human Cancer*, Foon KA And Morgan AC (eds). Martinus Nijhoff Publishing, Boston, 1985.
2. *Lymphomas/Leukemias III: Immunologic Approaches to the Classification and Management of Lymphomas and Leukemias*, Bennett JM and Foon KA (eds). Martinus Nijhoff Publishing, Boston, 1988.
3. *Biological and Hormonal Therapies of Cancer*, Foon K.A., Muss HB (Eds), Kluwer Academic Publishers, MA, USA, 1998.

## 3. Monographs

1. Foon KA and Schroff RW: The uses of monoclonal antibodies in the diagnosis and treatment of leukemia and lymphoma. In: *In Vitro Monograph*, No. 5. 1984, pp 169-188.
2. Foon KA: Application of monoclonal antibodies in the diagnosis and therapy of cancer. *NeoRx Monograph*, 1988, pp 1-27.

## 4. Book Reviews

Not applicable.

## 5. Editorials

1. Foon KA: Interferon-alpha: The next decade (editorial). *Interactions* 1:3, 1986.
2. Foon KA: Biological therapy of chronic myelogenous leukemia (editorial). *Oncology* 1:49-52 1987.
3. Vaickus L and Foon KA: Clinical immunology at Roswell Park Cancer Institute. Biotherapy of cancer (editorial). *Oncoline*, pp 3-4, 1990.

6. Letters to the Editor

1. Foon KA and Gale RP: Post-transfusion hepatitis in acute myelogenous leukemia. *JAMA* 246:216, 1981.
2. Foon KA, Zigelboim J and Gale RP: Treatment of acute myelogenous leukemia in older patients. *N Engl J Med* 305:1470, 1981.
3. Foon KA: Treatment of B-cell lymphoma with monoclonal anti-idiotypic antibody. *N Engl J Med* 307:686, 1982.
4. Bernhard MI, Foon KA, Oldham RK and Keenan A: The importance of traditional methods of measuring tracer biodistributions. *Cancer Res* 44:2731-2732, 1984.
5. Foon KA and Dougher G: Increased growth of eyelashes in a patient given leukocyte A interferon. *N Engl J Med* 311:1259, 1984.
6. Abrams PG, McClamrock EA and Foon KA: Evening administration of alpha interferon. *N Engl J Med* 312:443-444, 1985.
7. Reynolds CW, Foon KA and Herberman RB: Terminology in T $\square$  lymphoproliferative disease. *Blood* 66:248-249, 1985.
8. Foon KA, Gale RP: Is there a T-cell form of chronic lymphocytic leukemia. *Leukemia* 1992 Sep; 6(9):867-8. *Leukemia* 1993 June; 7(6):916-8.
9. Foon KA and Bhattacharya-Chatterjee M. Idiotypic vaccines in the clinic. *Nature Med* 4:870, 1998.

7. Abstracts

1. Foon KA, Wahl SM, Rosenstreich DL and Oppenheim JJ: Serotonin (5-hydroxytryptamine) induced lymphokine production from human peripheral blood lymphocytes. *Fed Proc* 34:1010, 1975.

2. Foon KA, Sher NA and Fishman ML: Macrophage chemotactic factor and migration inhibition factor in the aqueous humor during experimental uveitis. *Fed Proc* 35:492, 1976.
3. Foon KA, Naeim F and Gale RP: Acute myelogenous leukemia (AML): Morphologic subclass and response to therapy. *Blood* 52(Suppl 1):249, 1978.
4. Gale RP, Zighelboim J, Foon KA and Cline JJ: Intensive chemoimmunotherapy in acute myelogenous leukemia (AML). *Blood* 52(Suppl 1):250, 1978.
5. Naeim F, Zighelboim J, Foon KA, Gale RP and Walford RL: Acute myelogenous leukemia and HLA-DR antigens. *Blood* 52(Suppl 1):226, 1978.
6. Foon KA, Fitchen JH, Billing RJ, Belzer M and Cline MJ: Antigenic characteristics of human hematopoietic progenitor cells: Potential use in bone marrow transplantation. *Proceedings of the Conference on Aplastic Anemia*. HHH Publication No. 81-1008:294 1981.
7. Foon KA, Naeim F, Saxon A, Stevens R and Gale RP: Helper T-lymphocyte leukemia with clinicopathologic features similar to hairy cell leukemia. *Blood* (Suppl 1):187a, 1979.
8. Foon KA, Billing R, Belzer M, Fitchen J, Drew I and Terasaki P: A myeloid antigen defined by a heteroantiserum. *Blood* (Suppl 1):109a, 1979.
9. Foon KA, Billing RJ, Terasaki P and Cline MJ: Immunologic classification of acute lymphoblastic leukemia: Implications for normal lymphoid maturation. *Blood* (Suppl 1):186a, 1979.
10. Belzer M, Fitchen JH, Foon KA and Golde D: Monoclonal Ia-like (DR) antibody does not inhibit erythroid colony formation. *Blood* (Suppl 1):133a, 1979.
11. Foon KA, Fitchen JH, Belzer MB, Golde DW and Cline MJ: Hematopoietic stem cell antigens. *J Supramol Struct* (Suppl 4):35, 1980.
12. Foon KA, Zighelboim J and Gale RP: Long-term results of intensive chemotherapy of acute myelogenous leukemia. *Proc Am Soc Clin Oncol* 21:361, 1980.
13. Linker-Israeli M, Billing RJ, Foon KA, Fitchen JH and Terasaki PI: Monoclonal antibodies reactive with acute myelogenous leukemia (AML) cells. *Fed Proc* 40:1118, 1981.
14. Foon KA, Schroff RW, Bunn PA, Cline MJ and Fahey JL: Cell surface antigens defining functional T-cell subsets in Sezary cell leukemia. *Proc Am Assoc Cancer Res* 22:304, 1981.
15. Schroff R, Foon KA, Gee T, Fillipa D and Fahey J: Simultaneous expression of T and B surface markers by a subpopulation of leukemic phase lymphoma cells. *Proc Am Assoc Cancer Res* 22:304, 1981.

16. Foon KA and Schroff RW: Unique antigen expression of plasmacytoma cells associated with T lymphocytes with a suppressor phenotype. *Blood* 58(Suppl 1): 166a, 1981.
17. Foon KA, Schroff RW and Seeger RC: A monoclonal antibody recognizing human Thy-1: Distribution on normal and malignant hematopoietic cells. *Blood* 58(Suppl 1):129a, 1981.
18. Sherwin S, Knost J, Fein S, Abrams P, Foon K, Ochs J, Schoenberger C and Oldham R: A multiple dose phase I trial of recombinant leukocyte interferon using a 3 x weekly schedule. *Proc Am Soc Clin Oncol* 1:35, 1982.
19. Knost J, Sherwin S, Foon K, Abrams P, Ochs J, Schoenberger C and Oldham R: A phase I trial of lymphoblastoid interferon using a 6-hour intravenous infusion. *Proc Am Soc Clin Oncol* 1:35, 1982.
20. Bernhard MI, Foon KA, Clarke GC, Christensen WL, Hoyer L, Key M, Hanna MG and Oldham RK: A phase I trial of lymphoblastoid interferon using a 6-hour intravenous infusion. *Proc Am Soc Clin Oncol* 1:35, 1982.
21. Oldham RK, Bernhard MI, Key M, Peters LC, Brandhorst J, Hanna MG and Foon KA: Monoclonal antibody serotherapy of solid tumors: A guinea pig model II: *In vivo* studies. 13th Intl Cancer Congress, 1982.
22. Bernhard MI, Foon KA, Clarke GC, Christensen WL, Hoyer L, Key M, Hanna MG and Oldham RK: Monoclonal antibody serotherapy of solid tumors: A guinea pig model I: Characterization of monoclonal antibody. First Annual Congress of Hybridoma Research, 1982.
23. Zigelboim J, Foon K, Yale C and Gale RP: Treatment of acute myelogenous leukemia with intensive induction and consolidation chemotherapy. *Proc Am Soc Clin Oncol* 1:128, 1982.
24. Mitsuyasu R, McIntyre RM, Foon KA and Gale RP: A new syndrome of immune deficiency, hepatitis and aplastic anemia in young males.
25. Foon KA, Rossio J, Schroff RW, Wahl SM, Abrams PG, Rager H, Clarke G and Fidler IJ: Human T-T hybridomas secreting lymphokines. *Blood* 60(Suppl 1):72a, 1982.
26. Mayer D and Foon KA: Nursing implications of monoclonal antibody sero therapy. 8th Oncology Nursing Society Congress Proceedings: 48, 1983.
27. Schroff RW, Foon KA, Bunn PA, Sherwin SA and Oldham RK: Immunologic studies of chronic lymphocytic leukemia (CLL) and cutaneous T-cell lymphoma (CTCL) patients receiving monoclonal antibody therapy. *Fed Proc*.



28. Schroff RW, Klein RA and Foon KA: Antigen modulation in chronic lymphocytic leukemia (CLL) and cutaneous T-cell lymphoma (CTCL) patients undergoing monoclonal antibody therapy. Fed Proc.
29. Foon K, Rossio J, Schroff R, Abrams P, Rager H, Clarke G, Pickeral S and Fidler IJ: Human T-cell hybridomas secreting interleukin-2 (IL-2). Proc Am Assoc Cancer Res 24:220, 1983.
30. Foon K, Bunn P, Schroff R, Mayer D, Sherwin S, Longo D, Ochs J, Bottino G, Fer M, Herberman R and Oldham R: Monoclonal antibody therapy of chronic lymphocytic leukemia (CLL) and cutaneous T-cell lymphoma (CTCL). Proc Am Soc Clin Oncol 2:48, 1983.
31. Oldham RK, Hwang KM, Schroff RW, Pearson JW and Foon KA: Guinea pig hepatocarcinoma--A model for monoclonal antibody immunoconjugate testing. Fed Proc.
32. Fer MF, Abrams PG, Giardina S and Foon KA: Monoclonal antibodies in diagnostic oncology: Applications to the recognition of lung cancers. Proc Am Assoc Cancer Res 24:128, 1983.
33. Neubauer RH, Foon KA, Seeger RC and Rabin H: Monoclonal antibody reactivity with a Thy-1 determinant on normal and malignant hematopoietic cells of human and non-human primate origin. J Immunogenet vol.11, no. 3-4; (1984 June-Aug):233-43.
34. Oldham RK, Sherwin SA, Morgan AC, Foon KA, Abrams PG and Kimball ES: Monoclonal antibody (9.2.27) therapy of malignant melanoma. Proc Am Soc Clin Oncol 2:47, 1983.
35. Gale RP, Zighelboim J and Foon K: The role of maintenance chemotherapy in acute myelogenous leukemia. 3rd Intl Symp Therapy Acute Leukemias.
36. Foon KA, Bunn PA, Schroff WW and Oldham RK: Monoclonal antibody therapy of chronic lymphocytic leukemia (CLL) and cutaneous T-cell lymphoma (CTCL). Proc 5th Intl Congress of Immunology.
37. Schroff RW, Klein RA and Foon KA: Enhancing effect of monocytes upon cell surface antigen modulation: Implications to the therapeutic use of monoclonal antibodies. Proc 5th Intl Congress of Immunology.
38. Foon KA, Bernhard MI, Oeltmann TN, Hoyer LC, Hanna MG and Oldham RK: Monoclonal antibodies conjugated to naturally occurring toxins. Sym Discovery and Development of Naturally Occurring Antitumor Agents, 1983.
39. Woodhouse CS, Schroff R, Morgan A, Foon KA and Oldham R: Immunohistological assessment of localization of monoclonal antibody administered for therapy of malignant melanoma. Fed Proc, 1984.

40. Morgan AC Jr, Woodhouse CS, Knost JA, Foon KA and Oldham RK: Monoclonal antibodies to human colorectal tumor-associated antigens: Improved elicitation and subclass restriction. Third Annual Congress for Hybridoma Research, Fall;3(3):233-45, 1984.
41. Schroff RW, Carrasquillo JA, Foon KA, Keenan AM, Morgan AC Jr, Bunn PA, Reynolds HC, Perentesis P, Larson SM and Abrams PG: Clinical trials of radioimmunoconjugates of monoclonal antibodies for biodistribution and tumor diagnosis. Fed Proc, 1984.
42. Stevenson HC, Keenan AM, Stellar P, Miller P, Beman JA, Foon KA, Ottow R, Larson SM and Sugarbaker P: The fate of activated blood monocytes (IMO) into the peritoneum of patients with peritoneal colorectal carcinomatosis (PCC). Clin Res.
43. Foon KA, Schroff RW, Bunn PA Jr and Oldham RK: Effects of monoclonal antibody serotherapy on patients with chronic lymphocytic leukemia (CLL). Blood 62(Suppl 1):202a, 1983.
44. Bunn PA, Foon KA, Schroff RW, Hsu SM, Longo DL, Winkler CF and Oldham RK: T101 monoclonal antibody (MoAb) therapy for T-cell lymphomas. Blood 62(Suppl 1):210a, 1983.
45. Sherwin S, Foon KA, Bunn P Jr, Longo D and Oldham R: Recombinant leukocyte A nterferon in the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and mycosis fungoides. Blood 62(Suppl 1):215a, 1983.
46. Giardina SL, Schroff RW, Abrams PG, Woodhouse C, Rager HC, Morgan AC and Foon KA: Generation of murine anti-idiotypic monoclonal antibodies to B-cell-derived leukemias and lymphomas. Blood 62(Suppl 1):538, 1983.
47. Abrams PG, Giardina SL, Morgan AC, Oldham RK and Foon KA: The rapid generation of large quantities of human monoclonal immunoglobulins in highly concentrated nude mouse ascites: Implications for the development of murine anti-idiotypic monoclonal antibodies in leukemia and lymphoma. Blood 62(Suppl 1):186a, 1983.
48. Foon KA, Maluish AE, Abrams PG, Wrightington S, Schnipper EF and Herberman RB: A phase II trial of recombinant leukocyte  $\alpha$  interferon (rIFN- $\alpha$ ) for advanced hairy cell leukemia: Therapeutic and immunologic results. Blood 64(Suppl 1):164a, 1984.
49. Foon KA, Bottino GC, Abrams PG, Fer MF, Longo DL, Schoenberger CS and Oldham RK: A phase II trial of recombinant alpha interferon (rINF- $\alpha$ ) for advanced chronic lymphocytic leukemia (CLL). Blood 64(Suppl 1):164a, 1984.
50. Oldham R, Woodhouse C, Schroff R, Abrams P, Fer M, Kimball E, Foon KA and Morgan AC: Monoclonal antibody therapy of malignant melanoma: *In vivo* localization in cutaneous metastasis after intravenous administration. Proc Am Soc Clin Oncol 3:65, 1984.

51. Fer MF, Berman J, Stevenson HC, Maluish A, Moratz C, Foon KA, Herberman RB, Oldham RK with Terman DS, Young JB and Daskal IR: A trial of autologous plasma perfused over protein A in patients with breast cancer. *Proc Am Soc Clin Oncol* 3:63, 1984.
52. Bunn P, Foon KA, Ihde D, Longo D, Winkler C, Zeffren J, Oldham R and Sherwin S: Recombinant leukocyte  $\alpha$  interferon (IFL-rA) in the treatment of advanced refractory cutaneous T-cell lymphomas (CTCL). *Proc Am Soc Clin Oncol* 3:52, 1984.
53. Ruscetti F, Faltynek C, Abe H and Foon K: B-cell growth factor initiated lines from patients with hairy cell leukemia: No interferon effect on cell growth. *Blood* 66(Suppl 1):228a, 1985.
54. Foon KA, Nakano GM, Koller CA, Longo DL and Steis RG: Rapid response to 2'deoxycoformycin (DCF) after failure of recombinant leukocyte  $\alpha$  interferon (rIFN-A) in two patients with hairy cell leukemia (HCL). *Blood* 66(Suppl 1):199a, 1985.
55. Foon KA, Carrasquillo JA, Read EJ, Carter CS, Keenan AM, Reynolds HC, Perentesis P and Larson
56. Mulshine J, Keenan A, Carrasquillo J, Weinstein J, Reynold J, Larson S, Foon K and Bunn P: Successful immunolymphoscintigraphy after lymphatic delivery of  $^{111}\text{In}$ -T101. *Proc Am Soc Clin Oncol* 4:205, 1985.
57. Foon KA, Maluish AE, Abrams PG, Wrightington CS, Schnipper EF and Herberman RB: A phase II trial of recombinant leukocyte  $\alpha$  interferon (rIFN-A) for advanced hairy cell leukemia. *Proc Am Soc Clin Oncol* 4:221, 1985.
58. Bunn P, Carrasquillo J, Mulshine J, Keenan A, Foon K, Schroff R, Reynolds J and Larson S: Successful imaging of cutaneous T-cell lymphoma (CTCL) patients with intravenous  $^{111}\text{In}$ -T101. *Proc Am Soc Clin Oncol* 4:221, 1985.
59. Abrams PG, Carrasquillo J, Schroff R, Morgan AC, Fer M, Keenan A, Larson S and Foon KA: Successful imaging of metastatic melanoma with an indium-labeled monoclonal antibody. Tumor localization and biodistribution studies. *Proc Am Soc Clin Oncol* 4:228, 1985.
60. Woodhouse CS, Schroff RW, Foon KA and Morgan AC Jr: Factors affecting localization of murine monoclonal antibody 9.2.27 administered to patients with malignant melanoma. *Proc Am Assoc Cancer Res* 26:289, 1985.
61. Carrasquillo JA, Mulshine JL, Bunn PA, Reynolds JA, Foon KA, Schroff RW, Perentesis P, Stein RG, Keenan AM and Larson SM: Differences in biodistribution of I-131 and In-111 labeled T101 in patients with cutaneous T-cell lymphoma. Society of Nuclear Medicine 33rd Annual Meeting, Washington DC Convention Center, June 22-25, 1986.

62. Munz D, Carrasquillo JA, Newmann RD, Reynolds JC, Abrams P, Foon KA, Bunn PA, Mulshine JL, Schroff R, Morgan C and Larson SM: Dose-dependent differences in biodistribution of In-111 labeled monoclonal antibodies (MoAb). Society of Nuclear Medicine 33rd Annual Meeting, Washington DC Convention Center, June 22-25, 1986.
63. Roth MS, Carey JL, Foon KA, Harnden CE and Ginsburg D: Discordance of surface phenotype and immunoglobulin genotype: Leu 9 positive acute lymphoblastic leukemia of B-lineage. *Blood* 68(Suppl 1):250a, 1986.
64. Sinkule JA, Buchsbaum DJ, Fodor P, Hanna D, McQuiston S, Stites S, Foon KA, Kaminski M, Lichter A and Miller RA: Anticancer drug/radionuclide/monoclonal antibody. Second International Conference on Monoclonal Antibody Immunoconjugates for Cancer, UCSD Cancer Center, San Diego, California, March 12-14, 1987.
65. Huard TK, Heaphy BA, Ruscetti F and Foon K: Leukemic hairy cells resist NK cell lysis. *Proc Am Assoc Cancer Res* 28:1499, 1987.
66. Eger RR, Covell DG, Carrasquillo JA, Abrams PG, Foon KA, Reynolds JC, Schroff RW, Morgan AC, Larson SM and Weinstein JN: A kinetic model for the biodistribution of an <sup>111</sup>In-labeled antimelanoma monoclonal antibody in humans. *Proc Am Assoc Cancer Res* 28:1555, 1987.
67. Sinkule JA, Buchsbaum DJ, Foon K, Kaminski M and Miller RA: Therapeutic potential of dosocuribin/antibody/radionuclide conjugates in a B-cell lymphoma model. *Proc Am Assoc Cancer Res* 28:1575, 1987.
68. Foon KA: Diagnosis and therapeutic applications of monoclonal antibodies in leukemias and lymphomas. 18th International Leukocyte Culture Conference, La Grande-Motte, France, June 19-24, 1987.
69. Carrasquillo JA, Mulshine JM, Reynolds JC, Schroff RW, Bunn PA, Steis RG, Perentesis P and Larson SM: Radioimmunoscintigraphy of chronic lymphocytic leukemia (CLL) with monoclonal antibodies. 34th Annual Meeting Society of Nuclear Medicine, Metro Toronto Convention Centre, June 2-5, 1987.
70. Huard TK, Heaphy BA, Sennowitz K, Ruscetti F and Foon KA: Susceptibility of leukemic hairy cells to cytolytic effector cells. 29th Annual Meeting, The American Society of Hematology, September 1, 1987.
71. Buchsbaum DJ, Sinkule JA, Stites MS, Fodor PA, Hanna DE and Foon KA: Localization and therapy with radiolabeled monoclonal antibodies (MoAb) in nude mice bearing human B-cell lymphoma. 29th Annual Meeting, The American Society of Hematology, September 1, 1987.

72. Foon KA: Diagnosis and therapeutic applications of monoclonal antibodies in leukemias and lymphomas. 18th International Leukocyte Culture Conference, La Grande-Motte, France, June 19-24, 1987.
73. Huard TK, Heaphy BA, Ruscetti F and Foon K: Leukemic hairy cells resist NK cell lysis. Proc Am Assoc Cancer Res 28:1499, 1987.
74. Eger RR, Covell DG, Carrasquillo JA, Abrams PG, Foon KA, Reynolds JC, Schroff RW, Morgan AC, Larson SM and Weinstein JN: A kinetic model for the biodistribution of a <sup>111</sup>In-labeled antimelanoma monoclonal antibody in humans. Proc Am Assoc Cancer Res 28:1555, 1987.
75. Sinkule JA, Buchsbaum DJ, Foon K, Kaminski M and Miller RA: Therapeutic potential of doxorubicin/antibody/radionuclide conjugates in a B-cell lymphoma model. Proc Am Assoc Cancer Res 28:1575, 1987.
76. Buchsbaum DJ, Terry VH, Brubaker PG, Stites MS, Hanna DE, Fodor PA and Foon KA: Radiolabeled monoclonal antibody (MoAb) localization and therapy *in vitro* and in human cancer in nude mouse models. Radiation Research Society, 36th Annual Meeting; North American Hyperthermia Group, 8th Annual Meeting, 1987.
77. Sinkule JA, Buchsbaum DJ, Fodor P, Hanna D, McQuiston S, Stites S, Foon K, Kaminski M, Lichter A and Miller RA: Anticancer drug/radionuclide/monoclonal antibody (MoAb) conjugates: Therapeutic potential in a B-cell lymphoma model. Immunoconjugates, San Diego, 1988.
78. Foon KA: Interferon therapy for lymphomas. Interferon in Oncology, Espoo, Finland, June 16-17, 1988.
79. Goldrosen MH, Loftus R, Lloyd F Jr, Biddle W, Paolini N Jr, Holyoke ED and Foon KA: Localization of monoclonal antibody in a novel nude mouse model of pancreatic cancer. Proc Am Assoc Cancer Res 29:419, 1988.
80. Buchsbaum D, Sinkule J, Stites M, Fodor P, Hanna D and Foon K: Radiolabeled monoclonal antibody localization and therapy in nude mice bearing human B-cell lymphoma. Proc Am Assoc Cancer Res 29:424, 1988.
81. Foon KA: Immunologic classification of leukemia and lymphoma: Implications for monoclonal antibody diagnosis and therapy. ACNP/DOE/SNM Joint Symposium on Biology of Radionuclide Therapy, Washington DC, 1988.
82. Han T, Dadey B, Sheedy D, Xiao H, Block AW, O'Donnell A, Bhargava A, Fitzpatrick J, Roth MS, Foon KA and Henderson ES: Establishment and characterization of leukemic cell lines from patients with adult B-cell leukemias. Blood 72(Suppl 1):203a, 1988.

83. Foon KA: Immunologic classifications of leukemia and lymphoma: Implications for monoclonal antibody diagnosis and therapy. *Biology of Radionuclide Therapy Proceedings*, September 29, 1988.
84. Chatterjee M, Biddle W, Foon K and Köhler H: Anti-idiotypic (Id) antibodies against monoclonal antibody to carcinoembryonic antigen (CEA). *FASEB J* 3:828, 1989.
85. Chatterjee M, Foon K, Seon BK, Barcos M and Köhler H: Anti-idiotypic monoclonal antibody immunization therapy of cutaneous T-cell lymphoma. *Proc Am Assoc Cancer Res* 30:382, 1989.
86. Biddle W, Pancook J, Vaickus L, Goldrosen M and Foon KA: Immunologic and biologic studies of a Lym-1 ricin conjugate. *Proc Am Assoc Cancer Res* 30:395, 1989.
87. Goldrosen M, Biddle W, Bakshi S, Paolini N, Pancook J, Morgan AC Jr and Foon KA: Radiolocalization of NRLU-10 monoclonal antibody in a murine model of experimental hepatic metastases. *Proc Am Assoc Cancer Res* 30:393, 1989.
88. Biddle W, Loftus R, Paolini N, Pancook J, Foon K and Goldrosen M: Construction of a heterobifunctional antibody directed against carcinoembryonic antigen and phthalate. *Proc Am Assoc Cancer Res* 30:358, 1989.
89. VanderMolen L, Duffey L, Urba W, Longo D, Foon K, Smith J II, Clark J, Creekmore S, Hartmann I, Jaffe E, Miller R, Conlon K, Crum F, Stevenson H, Watson T and Steis R: Low-dose (LD) vs high-dose (HD) recombinant interferon alpha-2a (IFN) treatment in favorable histology non-Hodgkin's lymphoma (NHL). *Proc Am Soc Clin Oncol* 8:255, 1989.
90. Friedman N, Bernstein Z, Goldrosen M, Krajewski C, Vesper D, Steel J, Arbutck S, Sweeney J, Henderson E, Takita H, Kopec I, Levitt D, Stewart C and Foon KA: Phase II trial of IL-2/LAK therapy for patients with Hodgkin's disease (HD), non-Hodgkin's lymphoma (NHL) and non-small cell (NSC) lung cancer. *Proc Am Soc Clin Oncol* 8:194, 1989.
91. Massaro A, Ward MM, Evans SS, Stewart C, Foon K and Ward RE: Preferential expression of the gamma, delta TCR in T cells infiltrating B-cell lymphomas. *Proc Am Assoc Cancer Res* 30:343, 1989.
92. Foon KA, Miller RA, Barcos M, Han T, Hart S, Bernstein Z and Chatterjee M: Shared idiotype expression by B-cell leukemia/lymphoma: Unique restricted idiotype identified on diffuse lymphomas. *Blood* 74(Suppl 1):119a, 1989.
93. Jones VE, McNamara-Ward M, Massaro A, Foon K, Stewart C and Ward RE: Characterization of gamma-delta T cells by flow cytometry. *Blood* 74:68a, 1989.

94. Biddle W, Pancook J, Goldrosen MH, Foon KA and Vaickus L: IL-2 enhances Lym-1-dependent cellular cytotoxicity of normal and cancer patient mononuclear cells against B lymphoma targets. *Blood* 835:224a, 1989.
95. Vaickus L, Biddle W, Cemerlic D and Foon KA: Gamma-interferon augments Lym-1-dependent, granulocyte-mediated tumor cell cytotoxicity. *Blood* 543:147a, 1989.
96. Bernstein ZP, Vaickus L, Friedman N, Rahman R, Arbuck S, Henderson E, Goldrosen M, Vesper D, Steel J, Stewart C and Foon KA: Interleukin-2 (IL-2) and lymphokine-activated killer cell (LAK) therapy of non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD). *Blood* 1056:279a, 1989.
97. Bhattacharya-Chatterjee M, Biddle W, Foon KA and Köhler H: Syngeneic monoclonal anti-idiotypic related to human carcinoembryonic antigen. *Proc Am Assoc Cancer Res* 31:279, 1990.
98. Arbuck SG, Biddle WC, Keesler C, Stewart C, Foon K, Schmeltzer R, Maguire R and Goldrosen MH: Tissue biodistribution and pharmacokinetic analysis of intraperitoneally (IP) administered <sup>90</sup>Yttrium (<sup>90</sup>Y)-labelled B72.3 reactive adenocarcinomas confined chiefly to the peritoneal cavity. 15th International Cancer Congress, Hamburg, August 16-22, 1990.
99. Biddle WC, Musser DA, Goldrosen MH and Foon KA: Selective destruction of malignant human B cells by a photoimmunotherapeutic approach *in vitro*. 15th International Cancer Congress, Hamburg, August 16-22, 1990.
100. Chatterjee M, Biddle W, Foon KA and Köhler H: Idiotypic vaccines against human gastrointestinal (GI) carcinoma. 15th International Cancer Congress, Hamburg, August 16-22, 1990.
101. Arbuck SG, Biddle WC, Keesler C, Stewart C, Foon KA, Schmelter R, Maguire R and Goldrosen MH: Pharmacokinetic analysis of intraperitoneally administered <sup>90</sup>Yttrium-labelled B72.3 reactive adenocarcinomas. *Proc Am Assoc Cancer Res* 31:174, 1990.
102. Biddle WC, Musser DA, Goldrosen MH and Foon KA: Selective destruction of malignant human B cells by a photoimmunotherapeutic approach *in vitro*. *Proc Am Assoc Cancer Res* 31:293, 1990.
103. Cemerlic DZ, Genco J, Zgoda L, Neubauer J, Foon KA, Dadey B, Han T and Vaickus L: Cytokine augmentation of Lym-1-dependent, granulocyte-mediated lysis (ADCC) of chronic lymphocytic leukemia (CLL) tumor cells. *Proc Am Assoc Cancer Res* 31:287, 1990.
104. Watanabe H, Stewart CC, Arbuck SG, Foon KA and Goldrosen MH: The effect of anti-CD3 on lymphokine activity killer cell induction. *Proc Am Assoc Cancer Res* 31:278, 1990.

105. Biddle WC, Goldrosen MH, Schroff R, Morgan AC, Gregor KR, Pancook JD and Foon KA: Characterization of an anti-variant HLA-DR monoclonal antibody. *Proc Am Assoc Cancer Res* 31:284, 1990.
106. Biddle WC, Bakshi, Krajewski C, Loftus R, Pancook J, Peacock J, Foon KA and Goldrosen MH: Radiolocalization of an anti-CEA monoclonal antibody with restricted specificity. *Proc Am Assoc Cancer Res* 31:264, 1990.
107. Bielat KL, Biddle W, Vaickus L, Goldrosen MH and Foon KA: Ultrastructural observations of the interaction of Lym-1 monoclonal antibody with Raji Burkitt lymphoma cells. *Proc Am Assoc Cancer Res* 31:269, 1990.
108. Henderson ES, Foon K, Stewart C, Kelly S and Dadey B: The use of CD5 DIM/CD5 bright expression in B-CLL as a clinical monitoring tool of therapy effectiveness. *Blood* 78(Suppl 1):465a, 1991.
109. Bernstein ZP, Walther PJ, Vaickus L, Goldrosen M, Vesper D, Huben R, Lynch W Jr and Foon KA: Treatment of renal cell carcinoma with Interleukin-2 (IL-2) and phenylalanine methyl ester (PME) pretreated lymphokine activated killer cells (LAK). *Proc Am Soc Clin Oncol* 10:181, 1991.
110. Bernstein ZP, Vaickus L, Goldrosen M, Vesper D, Takita H, Zeffren J and Foon KA: Interleukin-2 (IL-2) and lymphokine activated killer cell (LAK) therapy of non-small cell lung cancer (NSCLC). *Proc Am Soc Clin Oncol* 10:285, 1991.
111. Villalona-Calero M, Stewart C, Barcos M, Baiocchi M, Caligiuri M and Foon KA: Phenotypic characteristics of "prolymphocytoid" transformed (CLL/PLL) chronic lymphocytic leukemia (CLL) cells. *Proc Am Soc Clin Oncol* 10:230, 1991.
112. Goldrosen MH, Stewart C, Biddle W, Bakshi W, Foon KA, Abdel-Nabi H, Spaulding M, Doerr R, Schmelter R, Maguire R and Arbus SG: Biodistribution and pharmacokinetic (PK) analysis of intraperitoneally (IP) administered <sup>90</sup>Y-labeled B72.3 (<sup>90</sup>Y-CYT-103) in patients with TAG-72 reactive tumors. *Proc Am Assoc Cancer Res* 32:271, 1991.
113. Abdel-Nabi H, Spaulding M, Goldrosen M, Bakshi S, Foon KA, Evans N, Farrell E, Kiessler C, Gona J, Doerr R, Schmelter R, Maguire RT and Arbus S: Phase I clinical trial of intraperitoneally injected <sup>90</sup>Y-labeled B72.3 (CYT-103) MoAb for refractory colorectal adenocarcinomas confined to the abdominal cavity. Sixth International Conference on Monoclonal Antibody Immunoconjugates for Cancer, San Diego, CA. February 28-March 1, 1991.
114. Watanabe H and Goldrosen MH: Growth regulatory effects of medium obtained from peripheral blood mononuclear cell (PBMC) primed with anti-CD3 and r-Interleukin-2 (rIL-2). *Proc Am Assoc Cancer Res* 32:83, 1991.



115. Goldrosen MH, Loftus RJ and Foon KA: Binding and penetration of  $^{125}\text{I}$ -D14, an anti-carcinoembryonic antigen (CEA) monoclonal antibody (MoAb) in a novel tumor histoculture system. *Proc Am Assoc Cancer Res* 32:275, 1991.
116. Mukerjee S, Foon KA, Ceriani R, Köhler H and Bhattacharya-Chatterjee M: Syngeneic monoclonal anti-idiotypic antibodies against a monoclonal antibody to human breast cancer-associated antigen. *FASEB J* 5:A1713, 1991.
117. Bhattacharya-Chatterjee M, Foon KA, Zhang J, Petrelli N and Köhler H: Idiotypic matching: Level of expression of a network antigen idiotype in colon cancer patients' sera. *FASEB J* 5:A1356, 1991.
118. Foon KA, Rai KR and Gale RP: Chronic lymphocytic leukemia: New insights into biology and therapy. *Oncol Dig* 2:18-20, 1991.
119. Foon KA, Vaickus L, Osseroff A, Stoll H, Köhler H and Chatterjee M: Phase 1 trial of anti-idiotypic monoclonal antibody vaccine therapy for patients with cutaneous T-cell lymphoma. *Proc Am Soc Clin Soc* 11:337, 1992.
120. Mukerjee S, Foon KA, Ceriani R, Köhler H and Bhattacharya-Chatterjee M. Generation of anti-anti-idiotypic antibodies (Ab3) that recognize human breast cancer-associated antigen. FASEB J. 6:A2059, 1992.
121. Chakraborty M, Sherratt AJ, Foon KA, Ceriani R, Köhler H and Bhattacharya-Chatterjee M. Induction of human breast cancer-specific antibody response in cynomolgus monkeys by a murine monoclonal anti-idiotypic antibody. *Proc Am Assoc Cancer Res.*, 35:497, 1994.
122. Fleming DR, Henslee-Downey PJ, Harder EJ, Romond EH, Messino M, Macdonald JS, Rayens MK, Marciniak E, Bishop MR, Ciocci G, Thompson JS and Foon KA. Partially matched related donor allogeneic bone marrow transplantation (BMT) in recurrent acute lymphoblastic leukemia (ALL). *Blood* 84(suppl 1):10, 1994.
123. Foon KA, Bhattacharya-Chatterjee M, Chakraborty M, John WJ, Köhler H and Sherratt AJ. Murine anti-idiotypic (Id) monoclonal antibody (mAb) induces specific humoral responses to carcinoembryonic antigen (CEA) in colorectal cancer (CRC) patients. *Proc Am Soc Clin Oncol*. Dallas, TX, May 1994.
124. Maloney DG, Bodkin D, Grillo-Lopez AJ, White C, Foon KA, Schilder R, Neidhart J, Janakiraman N, Waldichuk C, Varns C, Royston I and Levy R. IDEC-C2B8: Final report on a phase II trial in relapsed non-hodgkin's lymphoma. *Blood* 84(suppl 1):10, 1994.
125. White CA, Grillo-Lopez AJ, Maloney D, Bodkin D, Schilder R, Foon KA, Neidhart J, Janakiraman N, Dallaire B, Shen D, Royston I, and Levy R. PIDE-C2B8: Improved tolerance correlated with pharmacodynamic effects in patients with B-cell NHL. *Proc Am Assoc Cancer Res* (in press)

126. Chatterjee SK, Tripathi PK, Qin H-X, Xu C, Foon KA and Bhattacharya-Chatterjee M. Construction of vectors for expression of functional anti-idiotypic antibody fragments. ASBMB/ASIP/AAI Joint Meeting, New Orleans, LA, June 2-6, 1996. FASEB J. 10(6):A1059, 1996.
127. Sen G, Chakraborty M, Foon KA, Reisfeld and Bhattacharya-Chatterjee M. An alternative strategy for inducing predominately IgG antibodies and T cell responses against disialoganglioside GD2 using an anti-idiotypic antibody. ASBMB/ASIP/AAI Joint Meeting, New Orleans, LA, June 2-6, 1996. FASEB J. 10(6):A1059, 1996.
128. Chakraborty M, Foon KA and Bhattacharya-Chatterjee M. Serological response patterns of colorectal cancer (CRC) patients immunized with an anti-idiotypic antibody. ASBMB/ASIP/AAI Joint Meeting, New Orleans, LA, June 2-6, 1996. FASEB J. 10(6):A1346, 1996.
129. Qin H-X, Tripathi PK, Xu C, Bhattacharya-Chatterjee M, Foon KA and Chatterjee SK. Significance of the variable domain order and linker for the activity of anti-idiotypic antibody fragments expressed in bacteria. Allerg Clin Immunol. 99:No 1, Part Z, 5214, 1997.
130. Foon KA, Sen G, Chakraborty M, Reisfeld R, Garrison J and Bhattacharya-Chatterjee M. Anti-Idiotypic (Id) monoclonal antibody (mAb) that induces a specific humoral response to the GD2 ganglioside in advanced melanoma patients. Amer Soc Clin Oncol. Annual Meeting, 1997,
131. Munn RK, Hutchins L, Garrison J, Sen G, Chakraborty M, Baral R, Romond E, Bhattacharya-Chatterjee M and Foon KA. Immune responses in patients with breast cancer treated with an anti-idiotypic antibody that mimics the human milk fat globulin HMFG) antigen. ASCO, May 16-19, 1998, Los Angeles, CA. Proc ASCO 17:428a, 1998.
132. Bhattacharya-Chatterjee M, Sen G, Baral R, Banerjee M, Garrison J, Reisfeld RA and Foon KA. Immune responses in advanced melanoma patients immunized with an anti-idiotypic (ID) antibody mimicking disialoganglioside GD2. ASCO, May 16-19, 1998, Los Angeles, CA. Proc ASCO 17:435a, 1998.
133. Foon KA, John WJ, Chakraborty M, Garrison J, Bard V and Bhattacharya-Chatterjee M. Clinical and immune responses in surgically resected colorectal cancer (CRC) patients treated with an anti-idiotypic (ID) monoclonal antibody that mimics carcinoembryonic antigen (CEA) with or without 5-fluorouracil (5-FU). ASCO, May 16-19, 1998, Los Angeles, CA. Proc ASCO 17:435a, 1998.
134. Reece D, Foon K, Chatterjee M, Howard D, Munn R, Teitelbaum A, and Phillips G. Use of the anti-idiotypic (ID) antibody (AB) vaccine 11D10 (TRIAB) after intensive therapy (IT) and autologous blood stem cell transplantation (ASCT) in patients (PTS) with metastatic breast cancer (MBC). Gene Therapy of Hematopoietic Diseases; 94(Suppl 1):397a, 1999.

135. Manna S, Tripathi PK, Qin H-X, Bhattacharya-Chatterjee M, Foon KA and Chatterjee SK. DNA vaccines based on the structure of an anti-idiotypic antibody (3H1) mimicking carcinoembryonic antigen (CEA). *Proc. Amer. Assoc. Cancer Res.* 40:323, 1999.
136. Foon KA, Lutzky J, Yanelli J, Hutchins L, Kashala O, Garrison J, Reisfeld RA, Teitelbaum A, Chatterjee M. Clinical and immune responses in melanoma patients immunized with an anti-idiotypic (ID) antibody mimicking GD2. *Proc. Amer. Soc. Clin. Oncol.* (ASCO Mtg.) May 15 – 18, 1999.
137. Zeytin HE, Tripathi PK, Bhattacharya-Chatterjee M, Foon KA and Chatterjee SK. Long lasting in vivo expression of transgene after immunization with a plasmid expressing the single chain variable fragment (scFv) of the anti-idiotypic antibody mimicking GD2 ganglioside. Abst. presented at Keystone Symposia on Molecular and Cellular Biology, April 13, 1999.
138. Reece D, Foon KA, Bhattacharya-Chatterjee M, Connaghan G, Holland K, Munn R, DiPersio J, Simpson D, Teitelbaum A and Phillips GL. Anti-idiotypic vaccination plus intensive therapy and autologous stem cell transplantation for patients with metastatic breast cancer. *Europ. J. Cancer* 35(Suppl 4):5353, 1999.
139. Foon KA, Lutzky J, Yanelli J, Hutchins L, Kashala O, Garrison J, Reisfeld RA, Teitelbaum A, Chatterjee M. Clinical and immune responses in melanoma patients immunized with an anti-idiotypic (ID) antibody mimicking GD2. *PROLEUKIN Second International Congress*, July 29 – August 1, 1999.
140. Foon KA, John WJ, Chakraborty M, Das R, Teitelbaum A, Chatterjee SK, Bhattacharya-Chatterjee M. Clinical and immune responses in resected colon cancer patients treated with anti-idiotypic monoclonal antibody vaccine that mimics the carcinoembryonic antigen. *J Clin Oncol.* 17:2889-2895, 1999.
141. Manna S, Chakraborty M, Bhattacharya-Chatterjee M, Tripathi PK, Qin H-X, Foon KA, Zetyin H and Chatterjee SK. Mimicry of an epitope on carcinoembryonic antigen (CEA) by a peptide derived from the anti-idiotypic antibody, 3H1. *Proc. Am. Assoc. Cancer Res.* 41:877, 2000.
142. Reece D, Foon KA, Chatterjee M, Connaghan DG, Holland HK, Howard D, Munn RK, Nath R, Raptis H, Klingemann, Teitelbaum A and Phillips GL. Vaccination with TriAb in conjunction with intensive therapy and autologous stem cell transplantation for patients with metastatic breast cancer. *Proc. of ASCO.* 19:388, 2000.
143. Qin H-X, Valentino J, Manna S, Tripathi PK, Bhattacharya-Chatterjee M, Foon KA, O'Malley BW and Chatterjee SK. Therapy of head and neck cancer by recombinant vaccinia virus expressing IL-2 in amurine model and evidence of immune suppression. *Proc Am Assoc Cancer Res* 42:818, 2001.

144. Safa M, Lutzky J, Chatterjee M, Sussman J, Bard V, Baral R, Das R, Saha A, Shukla R, Reisfeld R, Hutchins L, Bhatnagar A, Foon KA. TriGem anti-idiotypic (Anti-Id) Monoclonal antibody (MAb) treatment for stage III melanoma: results of a multicenter phase II trial. *Proc. of ASCO Mtg.* 5/13/01.
145. Chatterjee M, Lutzky J, Safa M, Sussman J, Bard V, Baral R, Das R, Saha R, Shukla R, Reisfeld R, Hutchins L, Bhatnagar A, Foon KA. Immune and clinical comparison of different adjuvants combined with TriGem: an anti-idiotypic (Anti-Id) monoclonal antibody (MAb) treatment for stage III melanoma. *Proc. of ASCO.* 5/01.
146. Bhatnagar A, Lowy A, Rohatgi N, Chatterjee M, Bard V, Baral R, Saha A, Das R. CeaVac anti-idiotypic (Anti-Id) monoclonal antibody (Mab) therapy of colon cancer patients: comparison of different routes of administration using an alugel preparation of vaccine. *Proc of ASCO.* 5/01.
147. Rohatgi N, Bhatnagar A, Lowy A, Chatterjee M, Bard V, Baral R, Saha A, Das R, Shukla R, John W, Foon KA. CeaVac anti-idiotypic (Anti-Id) monoclonal antibody (Mab) treatment for resected colorectal cancer (CRC): results of a phase II trial. *Proc. of ASCO.* 5/01.

#### 8. Other (Videos)

1. Foon KA: Interferons. Hoffmann La Roche, 1986.
2. Foon KA: Antibody Structure and Function. NeoRx, 1988.
3. Foon KA: Therapy of Acute Leukemia: Recent Progress and Future Directions. Wyeth, 1988.
4. Foon KA: Cancer Vaccine Therapy: New Approaches, Video Journal of Oncology, Secaucus, NJ 1993.

#### Grant Activity

##### Inactive Funded Grants

Louis Sklarow Memorial Fund, "Monoclonal Antibodies for B-Cell Lymphomas," Kenneth A. Foon, M.D., Principal Investigator, 7/1/86 - 6/31/87, \$42,000 (total cost).

NIH 1 RO1 CA43212-01, "Mechanisms of Interferon Action in Hairy-Cell Leukemia," Kenneth A. Foon, M.D., Principal Investigator, 9/30/86 - 6/30/89, \$173,960 (total direct cost).

NIH PO1 CA42768, "Radiopharmaceutical Diagnosis and Treatment of Cancer," Subproject: "Preclinical and Clinical Treatment with Monoclonal Antibodies to B-Cell Lymphomas," Kenneth A. Foon, M.D., Principal Investigator, 9/30/87 - 2/28/89, \$265,803 (total direct cost).

"A Phase I/II Study of High-Dose, Continuous-Infusion Recombinant Human Interleukin-2 with Non-Small Cell Lung Cancer and Resistant Lymphoma," Kenneth A. Foon, M.D., Principal Investigator, Hoffmann La Roche, Inc., 10/1/88 - 9/30/89, \$50,000 (total cost).

"A Phase I/II Clinical Investigation to Evaluate the Safety and Efficacy of Continuous Infusions of Recombinant Interleukin-2 and Phenylalanine Methyl Ester Pretreated Cells in Patients with Unresectable and/or Metastatic Melanoma and Renal Cell Cancer," Kenneth A. Foon, M.D., Principal Investigator, Dupont Corporation, 1/1/89 - 12/31/90, \$270,000 (total cost).

NIH RO1 CA47860, "Idiotypic Approach to Therapy of Human T-Cell Leukemia," Malaya Chatterjee, Ph.D., Principal Investigator, Kenneth A. Foon, M.D., Co-Investigator (10%), 4/1/89 - 3/31/92, \$381,495 (total direct cost).

"Therapy of Renal Cell Carcinoma and Malignant Melanoma with Interleukin-2," Kenneth A. Foon, M.D., Principal Investigator (5%), Hoffmann La Roche, Inc., 6/1/90 - 5/31/91, \$39,000 (total cost).

NIH 1P01 CA4767-03 (Consortium), "Monoclonal Antibody Therapy of Breast Cancer," R. Ceriani, M.D., Program Director; "<sup>111</sup>Indium-Labeled Monoclonal Antibody Imaging of Metastatic Breast Cancer," Kenneth A. Foon, M.D., Principal Investigator (5%), 1/2/91 - 8/31/91, \$96,025 (total direct cost).

Buffalo Foundation Grant 857-0484A, "Feasibility Study of Anti-Idiotypic Monoclonal Antibody Therapy for Patients with Cutaneous T-Cell Lymphoma," Kenneth A. Foon, M.D., Principal Investigator (5%), 3/1/91 - 2/29/92, \$7,000 (total cost).

NIH 1P01 CA58880-01A2 (Program Project Grant), "Monoclonal Antibody Therapy for GI Cancer," Kenneth A. Foon, M.D., Principal Investigator (20%), 9/1/91 - 8/31/94, \$900,000 (total direct cost).

NIH RO1 CA54321-01 (Consortium), "Structure-Function of Tumor-Anti-Idiotypic Antibodies," Heinz Köhler, M.D., Ph.D., Principal Investigator; "Generation of Tumor-Anti-Idiotypic Antibodies," Malaya Chatterjee, Ph.D., Principal Investigator, Kenneth A. Foon, M.D., Co-Investigator (10%), 7/1/91 - 6/30/94, \$130,902 (total direct cost).

Share Foundation, "Phase Ib Study of Monoclonal Anti-Idiotypic Antibody Therapy for Patients with Metastatic Melanoma," 1/1/93 - 12/31/95, \$125,000 (total cost).

Ortho Pharmaceutical Corp. - Treatment of previously untreated chronic lymphocytic leukemia, 1994-95, \$50,000.

Tobacco & Health, Anti-Idiotypic Vaccine for Human Small Cell Lung Carcinoma, 7/1/94-6/30/95, \$79,900 (total direct cost).

NCI 1P01 CA57165-04 (Program Project Grant), "Monoclonal Antibody Therapy of GI Cancer", Kenneth A. Foon, M.D., Principal Investigator. Project 1. "Generation of Anti-Idiotypic Tumor

Vaccines", M. Chatterjee, Ph.D., Principal Investigator. 9/30/91 - 8/31/95, \$768,027 (direct cost), \$126,221 (indirect cost).

Berlex, Treatment of previously untreated low grade follicular lymphoma, Kenneth A. Foon, M.D., Principal Investigator, 1994-95, \$51,000.

NCI 5U10 CA46136-07, Southwest Oncology Group Clinical Study, Kenneth A. Foon, M.D., Principal Investigator, 1/1/88 - 12/31/97, \$507,164 (direct cost), \$244,266 (indirect cost).

NIH R01 CA60000-02, Anti-Idiotypic Vaccine for Breast Cancer, Kenneth A. Foon, M.D., Principal Investigator, 12/1/94 - 11/30/97, \$477,406 (total direct cost), \$233,929 (indirect cost).

P20-, Planning Grants for Prospective Cancer Centers, Kenneth A. Foon, M.D., Principal Investigator, 8/1/95 - 7/30/97, \$350,000 (direct cost), \$171,500 (indirect cost).

NCI R03 CA72468-01, Comparison of Alum and QS-21 Based Anti-Idiotypic Vaccines, Kenneth A. Foon, M.D., Principal Investigator, 12/1/96 - 11/30/98, \$147,000 (direct and indirect cost).

NCI U01 CA65748-01, New Therapeutic Approaches to Breast Cancer, Kenneth A. Foon, M.D., Principal Investigator, 12/1/94 - 11/30/98, \$842,019 (direct cost), \$412,589 (indirect cost).

NIH NCI U01CA65748, "New Therapeutic Approaches to Breast Cancer", Principal Investigator, Kenneth A. Foon, M.D., 1/1/95 - 12/31/99.

NIH NCI R03 CA68629, "Comparison of Alum and QS-21 Based Anti-Id Vaccine", Principal Investigator Kenneth A. Foon, M.D., 11/01/96 - 10/31/99

NIH NCI R01 CA72773-03, "Immunotherapy of Cancer with Anti-Id Based DNA Vaccines", Principal Investigator, Sunil K. Chatterjee, Ph.D., 10/01/99- 12/31/99.

Lucille P. Markey Charitable Trust, Research Program Grant, Kenneth A. Foon, M.D., Principal Investigator, 1/2/95 - 2/15/99, \$1,900,000 (total direct cost).

NIH R03 CA79401-01, Anti-Idiotypic Vaccine with IL-2 for Advanced Melanoma, Kenneth A. Foon, M.D., Principal Investigator, 11/1/98 - 10/30/00, \$145,646 (total direct and indirect cost).

Amgen, High Grade Lymphoma, Kenneth A. Foon, M.D., Principal Investigator, 2/1/95 - 2/1/99, \$15,000 (\$11,910 direct costs, \$3,090 indirect cost).

NIH R01 CA72018-01, Ganglioside GD2 as Target for Immunotherapy in Melanoma, Kenneth A. Foon, M.D., Co-Investigator, 8/1/96 - 6/30/01, \$1,142,854 (direct cost), \$1,679,995 (total cost).

#### Active Funded Grants

Titan Pharmaceutical, Inc., Anti-Idiotypic Antibody Vaccines, Kenneth A. Foon, M.D., Co-Principal Investigator, 7/1/96 - 6/30/01, \$1,750,000 (total direct cost). (Malaya Chatterjee, Ph.D., Co-Principal Investigator).

NIH RO1 CA86025-01, "Anti-Idiotypic Vaccine Therapy of Human Colorectal Cancer", Kenneth A. Foon, M.D., Co-Investigator, 9/01/00 – 8/31/03, \$1,818,570.00 (total direct cost). (Malaya Chatterjee, Ph.D., Principal Investigator).

NIH R01 CA72018-01, Ganglioside GD2 as Target for Immunotherapy in Melanoma, Kenneth A. Foon, M.D., Principal Investigator, 9/01/01 – 8/30/06, \$1,250,000.00 (total direct cost). (Malaya Chatterjee, Ph.D., Co-Investigator).

NIH R01 CA91878-01 HER2/Neu: A Target for Cancer Immunology. Kenneth A. Foon, M.D., Co-Investigator, 9/1/01 – 8/30/06, \$1,125,000.00 (total direct cost). (Malaya Chatterjee, Ph.D., Investigator).

Grants Pending:

None.

Patents

**Tri-Gem (1A7)**

Patent Number: 5,612,030

Date of Patent: 3/18/97

"Anti-idiotypic monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma"

**TriAb (11D10)**

Pending Serial Number: 08/766,350

Date Filed: 12/13/96

"Murine monoclonal anti-idiotypic antibody 11D10 and methods of use thereof"

**CeaVac (3H1)**

Pending Serial Number: 08/579940

Date Filed: 12/28/95 (whole antibody)

"Murine monoclonal anti-idiotypic antibody 3H1"

Pending Serial Number: 08/579916

Date Filed: 12/28/95

"Recombinant monoclonal anti-idiotypic antibody 3H1 sequences relating to human carcinoembryonic antigen"

## Proceedings of ASCO Volume 20 2001

1008

ORAL PRESENTATION, SUN, 12:45 PM - 4:45 PM

**Trigem Anti-Idiotypic (Anti-Id) Monoclonal Antibody (MAb) Treatment for Stage III Melanoma: Results of a Multicenter Phase II Trial.** *M. Safa, J. Lutzky, M. Chatterjee, J. Sussman, V. Bard, R. Baral, R. Das, A. Saha, R. Shukla, R. Reisfeld, L. Hutchins, A. Bhatnagar, K. A. Foon; University of Cincinnati, Cincinnati, OH; Mt. Sinai Cancer Center, Miami Beach, FL; Barrett Cancer Center, University of Cincinnati, Cincinnati, OH; The Scripps Research Inst., La Jolla, CA; University of Arkansas, Little Rock, AK; Titan Pharmaceuticals Inc., South San Francisco, CA*

TriGem is an anti-Id MAb that functionally mimics disialoganglioside GD2 which is highly expressed on melanoma cells. Sixty-nine patients with AJCC stage III melanoma were treated with TriGem. Of these, 25 also received high dose interferon (HDI) in addition to TriGem. Patients received the vaccine weekly for 4 weeks and then monthly until disease recurrence. Median age was 52 years (17- 86 years), 45 were males and 24 were females. There were 28 patients with N1 disease (1 node positive), 26 with N2 disease (2 to 3 positive nodes), 8 with N3 disease (4 or more positive nodes), and 7 with unknown number. The overall survival (OS) and relapse-free survival (RFS) for all patients were 82% and 62% respectively with a median follow-up of 24 months. OS for patients treated with TriGem alone was 72% (7 deaths among 44 patients) and for HDI plus TriGem was 96% (1 death among 25 patients). RFS for patients treated with TriGem alone was 50% and for HDI plus TriGem was 80%. In the E1694 Intergroup trial (personal communication, Dr. John Kirkwood) 440 patients were treated with HDI. OS and RFS were 78% and 62% (compared with 96% and 80% for HDI plus TriGem) respectively at a median follow-up of 24 months. We also studied the immune responses of HDI plus TriGem versus TriGem alone and found no significant differences, demonstrating that HDI does not suppress the immune response to TriGem. Toxicity of the vaccine was generally mild with a local reaction with swelling and pruritis lasting for 24 to 48 hours. In conclusion, our data suggests a clinical benefit of TriGem in stage III melanoma at a median follow-up of 2 years, particularly for patients treated with HDI plus TriGem. A randomized trial for stage III melanoma patients treated with HDI versus HDI plus TriGem is planned.